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Signal transduction pathways in macrophages activated by lipopolysaccharide (LPS) are 
only beginning to be elucidated. The first step involves recognition of LPS by the cells 
primarily by the LPS receptor, CD 14. Different LPS and lipid A preparations, as well as 
lipoteichoic acids from Gram positive organisms, bind to CD 14 and activate signaling. 
However, they showed a wide range o f potencies in activating arachidonic acid 
metabolism. These data combined with current theories on supramolecular 
conformations o f bacterial amphiphiles, suggest a. model o f potency based on aggregate 
conformation and the availability o f monomers for binding to CD 14. Although not 
conclusive, this model provides a basis for exploration of variations in responsiveness to 
bacterial amphiphiles.
Ceramide is an important second messenger in immune cells, and it appears to share 
signaling components with LPS pathways. Studies on the hypothesis that LPS acts by 
mimicking ceramide have provided many clues to mechanisms of intracellular 
modulation o f responsiveness. LPS and ceramide both activated arachidonic acid 
metabolism, but only LPS induced the production of prostaglandin E2. This suggests a 
divergence in signaling pathways that may be related to pool compartmentalization of the 
signaling enzymes or their substrates. LPS, but not ceramide, was able to desensitize 
cells to subsequent challenge. This difference could either be due to a lack of a shared 
regulatory mechanism, or to an autocrine/paracrine effect related to the activation of 
prostaglandin production.
Responsiveness is also determined by the phosphorylation state o f tyrosine kinases of 
the src family. CD45 protein tyrosine phosphatase was shown to be involved in LPS- 
induced signaling through the use o f anti-CD4S monoclonal antibodies. Although the 
antibodies and their isotype controls had little or no effect on their own, anti-CD45 
significantly increased (2 -fold) the release of arachidonic acid metabolites, including 
prostaglandin E2 following LPS challenge. This effect was shown to be primarily 
involved in signaling through CD14, rather than CD 14-independent signaling.
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CHAPTER 1
OVERVIEW OF MACROPHAGE ACTIVATION AND DESENSITIZATION 
The role of the macrophage in the vertebrate immune system.
The vertebrate immune system functions as a dynamic balance between states 
of activation and states of tolerance, and many components of the system embody 
mechanisms to respond to various signals in a discriminating manner. Errors in 
discrimination or deviations in the delicate balance can lead to responses that are 
damaging to the organism. If poorly responsive, the immune system is ineffective in 
its protective role, but if overly responsive it can induce pathological consequences. 
Macrophages have proven to be at the hub of this process, playing significant roles in 
both cellular and humoral immune responses. They are large, adherent, mononuclear 
phagocytic cells which differentiate from circulating monocytes and migrate into 
various tissues. From this position o f influence, the macrophage’s activities must be 
carefully regulated in order to maintain a balance of responsiveness. Depending on 
the stimulus, several different signaling pathways lead to a variety o f responses, 
including cytokine release (especially TNFa, ILi, H*, ILg), oxidative burst, increased 
phagocytosis, and arachidonic acid metabolism. Macrophage activation is being 
studied regarding its involvement in multiple pathological responses including septic 
shock, asthma, stroke, and atherosclerosis (5,13,71,81). It is therefore conceivable 
that treatments or prevention of these diseases may evolve through the
1
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exploration o f mechanisms that influence the balance between the beneficial and 
pathological sequelae of macrophage activation.
Overview of signal transduction pathways
In order to understand the mechanisms of macrophage activation, it is necessary 
to understand the basics o f signal transduction, which entails the ability of a cell to 
detect and respond to extracellular signals. Signal transduction through cell surface 
receptors can be categorized into three large general groups. In one well characterized 
pathway, a transmembrane receptor activates a G (GTP-binding) protein, which then 
alters the activity of adenylate or guanylate cyclase. Activation of these enzymes 
results in the generation o f second messengers, including cyclic adenosine 
monophosphate (cAMP) or cyclic quanosine monophosphate (cGMP). In another 
family o f pathways, the receptor activates a specific phospholipase C, which cleaves a 
phosphodiester-linked side group from a phospholipid or sphingolipid. The cleavage 
products, such as inositol triphosphate, diacylglycerol, or ceramide can then serve as 
second messengers affecting a cellular response. Finally, some receptors activate 
protein kinases and phosphatases which in turn can initiate the cellular response by 
altering phosphorylation o f target proteins which are often enzymes or regulatory 
elements. This is the primary signaling system used by the antigen-binding receptors 
o f lymphocytes. Each o f these systems has mechanisms for shutting down the 
response when the signal is no longer present or a second signal overrides the first. 
Usually this is not a simple on/off switch, but rather a change in the balance or ratio 
between opposing signals that affects the final outcome. Therefore, the activation
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
3
state o f a cell depends on the expression of receptors, availability o f second 
messengers, and the ability to shut down the response.
Definition of activation states
Studies have shown that macrophages respond very differently depending on 
anatomical location, the nature of the stimulus, and the cell’s state o f differentiation. 
Strictly speaking, macrophage activation states probably lie on a continuum 
encompassing several hundred “forms of activation” (92). Attempts to characterize 
them as macrophage subsets according to location or surface markers have been 
unsuccessful (36). -For the purpose of this dissertation, only three states will be 
defined. These are “responsive”, “activated”, and “desensitized”.
A responsive macrophage is competent to respond to signals. It might be 
considered to be in a state o f vigilance, appropriate for the macrophage’s critical role 
in detection. These cells respond to a stimulus by releasing high levels o f cytotoxic 
and biologically active substances, many of which serve to signal other cells. Stimuli 
can include bacterial cell wall components, cytokines, and particles that are 
phagocytized. The activated macrophage can be further stimulated with synergistic 
signals and induced to release higher levels o f substances such as tumor necrosis 
factor a  (TNFa) and interleukins, but the mechanisms o f this additive response are not 
clearly understood (1,17,39). However, it is the excessive or unbalanced production 
o f these autocrine and paracrine mediators which has been implicated in multiple 
disease states.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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The desensitization phenomenon
At the other end of the continuum is a macrophage that has been desensitized and is 
hyporesponsive. There are several mechanisms that may induce this state. A fairly 
specific hyporesponsiveness is induced simply by saturating concentrations o f ligand 
or the internalization o f receptors, making them unavailable for binding (17). This 
requires a very specific receptor-ligand relationship, and the cell remains responsive to 
other stimuli. Similarly, a means to down-regulate responsiveness to a specific 
stimulus is to shed the receptor, and decrease its surface density (9). A more 
generalized hyporesponsiveness is induced in macrophages by glucocorticoids ( 110). 
The pathway is unclear, but it appears to be a natural mechanism for shutting down a 
response by decreasing the activity of enzymes such as the phospholipases. There is 
some evidence that this involves phosphorylation or dephosphorylation (47), and/or 
the release of autocrine mediators (110). A third mechanism o f  desensitization has 
been demonstrated as a fairly specific hyporesponsiveness by macrophages to a 
second exposure to bacterial cell wall amphiphiles such as lipopolysaccharide (LPS) 
from Gram negative microorganisms (42,96), and lipoteichoic acid (LTA) from Gram 
positive microorganisms (16). The state can be induced by concentrations of LPS far 
below saturation (17,28), and the cells remain responsive to other stimulators such as 
phorbol myristate acetate (PMA) which bypass early steps in the signaling cascade 
(16). This suggests that the mechanism of desensitization is an early event that lies 
between receptor binding and distal signaling. Others have provided some evidence 
that the process requires the release of autocrine mediators (28,41,76,84), although the
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data are not consistent enough to determine the precise factor(s) involved. 
Desensitization is characterized by dramatic reductions in the amount o f products 
released after subsequent challenge to, or below, constitutive levels.
Signal transduction in the activation of macrophages by LPS
Bacterial lipopolysaccharide (LPS) is a potent activator o f macrophages, but the 
signal transduction pathways for its numerous effects have not been clearly defined. 
LPS activates multiple pathways, resulting in the release o f cytokines, eicosanoids, 
and oxygen free radicals. Macrophages have several surface binding proteins for LPS, 
but only a few appear to be involved in signal transduction. In fact, they appear to be 
able to respond to LPS via both receptor-dependent and receptor-independent 
pathways (68,84,106,108). Differential activation of these pathways may depend on 
the concentration o f LPS, its supramolecular structure as it is presented to the cells, 
and/or the presence o f LPS binding proteins. Lipid A derivatives have been designed 
that retain immunostimulatory properties, but lack endotoxicity. These remain able to 
desensitize cells to LPS challenge, and are being explored as preventative treatments 
for pathological inflammatory reactions.
The primary receptor for LPS actually appears to bind a complex consisting of 
LPS and LPS binding protein (LBP). LBP is an acute phase protein found in the 
serum, that binds LPS in an apparent 1:1 stoichiometry. This offers a unique way to 
present LPS to cells. As an amphiphilic lipid, LPS is normally found in aggregates 
such as micelles. The receptor, CD 14, is a glycosylphosphatidylinositol-linked 
glycoprotein that has been shown to play a role in LPS-mediated macrophage
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activation (91,98) and desensitization (57,70). Since it lacks a cytosolic tail, it is still 
unclear how it participates in signal transduction. However, CD 14 is among several 
GPI-anchored proteins that are capable of mediating cell activation when cross-linked 
with monoclonal antibodies (67,88). CD 14 has also been shown to co-precipitate with 
associated proteins (91). Deacylated LPS binds CD14, but does not elicit responses, 
suggesting that another molecule associated with CD 14 is required to transduce the 
signal (57). In fact, Vasselon, et al. have recently shown that trypsin treatment 
reduced responsiveness to LPS in PMNs without any change in cell surface expression 
o f CD 14 (95). It is possible, therefore, that there is a receptor complex on 
macrophages which is analogous to the complexes on T cells and B cells. Signaling 
following binding to CD 14 has been shown to include protein tyrosine 
phosphorylation (43,60,98), release o f cytokines including TNFa, IL-1, and IL-6 
(57,98), calcium fluxes and release of oxygen free radicals (66 ). Involvement of 
CD 14 in the release o f eicosanoids is inferred by the dramatic increase in LPS-induced 
release of labeled arachidonic acid from THP-1 cells following induction of CD 14 
expression (Fig. 7 in Chapter 2).
Arachidonic acid metabolism
Arachidonic acid, a C20 polyunsaturated fatty acid (C20:4) is commonly esterified 
at the 571-2 position o f membrane glycerophospholipids. When released, usually by 
phospholipase A2 (PLA2), arachidonic acid becomes a substrate for several metabolic 
enzymes. Arachidonic acid and its family of metabolites constitute a very important 
group of paracrine and autocrine mediators called eicosanoids. Eicosanoids are
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rapidly released from macrophages following activation with various agents including 
LPS and PMA. Two of the major eicosanoids released from macrophages are 
prostaglandins (cyclo-oxygenase pathway) and peptidyl-leukotrienes (lipoxygenase 
pathway) (31,33,48,105). The ratio o f these two lipid families appears to be important 
in the regulation o f the immune response (100,105). Therefore, the study of 
arachidonic acid metabolism in macrophages is critical to the understanding of 
regulatory mechanisms in the cellular immune response.
RESEARCH OBJECTIVES 
This thesis focuses on the signal transduction leading to arachidonic acid 
metabolism in THP-1 monocytic cells, with an emphasis on regulatory mechanisms 
such as the desensitization phenomenon. Treatment strategies for inflammatory 
responses associated with Gram negative bacterial infections have ranged from 
palliative therapies, to cytokines given as pharmaceuticals, to monoclonal antibodies 
generated against LPS. Despite promising results in in vitro studies and animal 
models, none of these strategies has had much success in clinical studies to date. It 
seems valid to explore regulatory systems already in place in the immune system as 
possible mechanisms to exploit as therapeutic strategies. However, such studies will 
require cell systems that provide good models for human macrophage activation, a 
better understanding of how cells respond to LPS including specific signal 
transduction pathways, and elucidation of those pathways’ regulatory mechanisms.
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Major Objective #1: Characterization of the human monocytic cell line, THP-1, as 
an appropriate cell system for exploring macrophage activation, especially arachidonic 
acid metabolism.
Specific Aims: -
1. To study basic growth characteristics and determine ideal growth conditions.
2. To observe viability and morphological changes following treatments using 
trypan blue exclusion and microscopy to determine that cell losses due to death or 
adherence would not significantly impact assay results.
3. To measure lipid composition and pool labeling by thin layer 
chromatography and liquid scintillation counting to demonstrate that treatments did 
not cause alterations in these parameters that would impact assay results.
4. To measure surface expression o f CD14 using flow cytometry to determine 
whether treatments affected expression of this LPS receptor.
Major Objective #2. Compare the activation and desensitization of macrophages by 
various bacterial amphiphiles, using the hypothesis that the supra-molecular structure 
o f LPS and related molecules likely has an important influence on potency.
Specific Aims:
1. To measure 3H-arachidonic acid release from macrophages treated with 
various forms of LPS, lipid A, and LTA, the bacterial amphiphiles involved in septic 
shock.
2. To demonstrate desensitization of macrophages by these amphiphiles for 
arachidonic acid metabolism and release of pro-inflammatory cytokines.
3. To compare PGE2/LTC4 ratios released from treated cells, using EIA, to 
determine whether patterns can be seen in terms of the ability to desensitize cells to 
subsequent challenge.
Major Objective #3. Compare the effects o f LPS and ceramide as activators of 
arachidonic acid metabolism, based on the current thinking that LPS may mimic
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
ceramide as a second messenger. This model, if valid, would define many o f the 
signal transduction components in LPS pathways that have otherwise proven elusive. 
It could also be very important in the understanding o f septic shock syndrome due to 
the induction of apoptosis by ceramide and the recent evidence that a major part o f 
septic shock is widespread endothelial apoptosis of the micro vasculature of multiple 
organs. Development o f the LPS/ceramide mimicry model has been based primarily 
on studies of cytokine release, and similarities between signaling by TNF and LPS. It 
was therefore important to explore the model in terms o f arachidonic acid release. 
Specific Aims:
1. To determine whether exogenous cell-permeable ceramides and/or 
sphinomyelinase would activate arachidonic acid metabolism, and to compare that 
with LPS activation.
2 . To measure PGE2/LTC4 ratios released following these treatments to 
compare activation of these pathways (cyclo-oxygenase and S’-lipoxygenase).
3. To determine whether cell-permeable ceramide or sphingomyelinase could 
desensitize cells to subsequent challenge.
4. To correlate eicosanoid ratios with the ability to desensitize.
Major Objective #4. Determine whether or not the CD45 protein tyrosine 
phosphatase plays a role in the activation of macrophages by LPS. The hypothesis 
was that CD 14 might be part of a receptor complex on macrophages similar to antigen 
receptor complexes on T cells. CD45-deficient T cells are hyporesponsive to antigen 
binding due to hyperphosphorylation of the tyrosine kinases involved in the signaling 
pathway. It seemed possible that phosphorylation- dephosphorylation dynamics might
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therefore play a role in the desensitization phenomenon in macrophages by a similar 
mechanism.
Specific Aims:
1. To show expression of CD45 on THP-1 cells using flow cytometry, and to 
determine whether LPS altered this expression either in terms o f percent o f cells 
staining positive, or mean fluorescence.
2. To use specific monoclonal antibodies (mAb) to CD4S to determine their 
effect, if any, on arachidonic acid metabolism and cytokine release induced by LPS, 
either by binding or by being cross-linked.
3. To correlate CD45 involvement with signaling through the CD 14 pathways 
by performing assays under conditions favoring this pathway, and by using an anti- 
CD 14 mAb which binds the LPS binding site and activates the LPS pathways.
4. To determine whether CD45 plays a role in the desensitization phenomenon 
by adding anti-CD45 mAb during the desensitization period of the assays.
5. To use Western blotting to detect changes in the phosphorylation state of 
CD4S on cells following treatment with LPS, since autodephosphorylation is an 
indicator of enzyme activity for CD45.
The experimental studies addressing these objectives are presented in the 
following chapters.
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CHAPTER 2 
Characterization of THP-1 Cells as a Human Macrophage Model for 
Activation of Arachidonic Acid Metabolism
Introduction
Developing a model for studying macrophage activation is challenging due to the 
heterogeneity o f this cell type and the difficulties of working in vivo. Although it must be 
kept in mind that interactions between various cells types occur continuously under 
normal circumstances, monocultures of monocytes derived either as primary cultures 
harvested from blood or peritoneal fluid, or maintained as cells lines, can provide data 
regarding direct effects of treatments in vitro, while holding most variables constant. 
THP-1 is a human leukemic cell line with a normal diploid karyotype (29) that was 
cultured initially from a boy with acute monocytic leukemia (90). These cells express 
surface markers and respond similarly to human monocytes, and can be maintained in 
monoculture as a nonadherent suspension with a doubling time o f60 -  70 hours. They 
can be differentiated to a more macrophage-like phenotype by treating them with various 
agents, including phorbol myristate acetate (PMA), vitamin D3, or retinoic acid. 
Differentiated THP-1 cells behave more like monocyte-derived macrophages than other 
human myeloid cell lines, including HL-60, U937, KG-1, or HEL cells (4). THP-1 cells 
must be maintained between 2 -  5 x 10s cells/ml and not used after approximately 20 
passages due to losses in responsiveness. Most of the work for this thesis was done using 
THP-1 cells, but comparative studies were done on murine resident peritoneal
11
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macrophages harvested from Balb/C (Jackson Labs) mice, and RAW 264.7 cells. RAW 
264.7 cells (ATCC) are virally-transformed mouse peritoneal macrophages that form 
adherent monolayers in cell culture. They are well characterized as excellent models for 
the study of murine macrophage activation (43,96). They were, however, of limited use 
in studying arachidonic acid metabolism due to their constitutively high levels of 
arachidonic acid release.
There are very few good macrophage models, particularly for human cells. THP-1 
cells were developed as a model for differentiation and expression o f monocytic surface 
markers, but few studies have been done regarding their feasibility as a model for 
inflammation and particularly for lipid metabolism. My objective for the studies 
presented in this chapter was to characterize this cell line as a model for macrophage 
activation, appropriate for studies focusing on arachidonic acid metabolism. This 
included four specific aims. The first was to study basic growth characteristics and 
determine ideal growth conditions in order to get the most consistent results. Second, 
viability and morphological changes following treatments were observed using trypan 
blue exclusion and microscopy to determine that cell loss due to cell death or adherence 
would not significantly impact results. Third, we measured lipid composition and pool 
labeling by thin layer chromatography to demonstrate that treatments did not cause 
alterations of these parameters that would impact assay results. Finally, we measured the 
surface expression of CD 14 using flow cytometry to determine whether treatments 
affected expression of this LPS receptor.
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Amphiphiles and reagents. All LPS and lipid A preparations were provided by 
Ribi ImmunoChem Research (Hamilton, MT). Stock solutions o f amphiphiles at 1000 
pg/ml were kept at 4° C in 0.1% triethylamine (TEA). LTA from E. faecalis, PMA, 
dexamethasone, N-acetyiceramide, phospholipid and sphingolipid standards for thin layer 
chromatography, and 2-mercaptoethanol were obtained from Sigma. Vitamin D3 ( la , 25 
dihydroxyvitamin D) was purchased from Calbiochem (LaJolla Ca). [3H]-arachidonic 
acid was purchased from American Radiolabeled Chemical Co. (St. Louis, MO). 
Minicolumns for lipid separations were purchased from Amersham. Monoclonal 
antibodies for flow cytometry were from Becton-Dickinson Immunocytometry Systems 
(San Jose CA) and Coulter Laboratories.
Cell Culture. THP-1 cells from ATCC were cultured in RPMI from Mediatech, 
supplemented with 10% Hyclone fetal bovine serum (FBS) and 2 x 10'5 M 2- 
mercaptoethanol at 37° C in a 5% CO2 incubator. Cells were maintained between 2.5 x 
10s and 1 x 106 cells/ml. Prior to experiments, cells were incubated overnight with a 
maturation agent, either 10'7 M vitamin D3 or 2 nM PM A Although loosely adherent, 
cells could be removed by pipeting or gentle scraping.
Lipid analysis. Lipids were extracted from THP-1 cells by a modification of the 
Bligh and Dyer procedure (12). THP-1 cells were grown in either 32P or 3H-AA (0.5 
pCi/ml) to label the lipid pools. Cells were suspended in 1 ml cold NaCl (0.3%) and then 
heated at 6 8° C in an additional 3 ml of solvent containing chloroform:methanol: 1 N HC1
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(1:2:0.3 v/v) for 5 min. The cooled suspension was centrifuged and the supernatant (lipid 
extract) was transferred to a clean centrifuge tube The cell residue (pellet) was extracted 
again with 1.9 ml o f solvent containing chloroformrmethanol: 0.3% NaCl ( 1:2 :0 .8  v/v). 
The combined extracts were mixed thoroughly with 1.5 ml chloroform and 1.5 ml 0.3% 
NaCl. This mixture of chloroform:methanol:water (2:2:1.8 v/v) provided a two phase 
system that was separated by centrifugation. The chloroform phase was removed and 
taken to dryness, and resuspended in chloroform:methanol (2:1 v/v). Total lipid extracts 
were analyzed by thin layer chromatography on Whatman LD6D plates using a solvent 
system consisting o f chloroform-ethanol-water-diethylamine (30:34:8:35 v/v). To 
quantify the lipids (32P-labeled phospholipids, or 3H-AA) in each band, the bands were 
scraped from the plates and counted in a liquid scintillation spectrometer.
Lipids released from activated cells were also separated into prostaglandin, 
peptidoleukotriene, and fatty acid fractions on Amprep C l8 minicolumns (Amersham) 
using the following solvent system: (solvent A); acetonitrile-methanol-water-acetic acid 
(8:5:12:0.025 v/v). After washing the column with water, prostaglandin E2 and related 
compounds were eluted with solvent A-water (75:25), peptidoleukotrienes with solvent 
A-methanol (50:50), and arachidonic acid with methanol.
Challenge experiments
Eicosanoid release. Differentiated THP-1 cells were labeled overnight with 0.5 
|iC/ml 3H-AA (specific activity = 200 Ci/mmole) in RPMI with 10% FBS, then washed 
three times with warmed RPMI. Cells were then gently removed from flasks and plated 
in 24-well plates at approximately 1.5 x 106 cells/well in 0.5 ml RPMI. Challenge
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concentrations (2x) were added, 0.5 ml/well in RPMI with 4% FBS. Plates were 
incubated for 2 hr at 37° C. Supernatants were removed to microfuge tubes and spun at 
3000 rpm for 3 min to remove any cells. 200 pi of the cell-free supernatants were 
counted in a Beckman scintillation spectrometer. For uptake experiments, 200 pil of 
supernatants before challenge (counts not taken up), and 200 pi of cell lysates (1 ml 1% 
Triton X100) from each sample (uptake) were also counted.
Cytokine release. Differentiated THP-1 cells were plated in 24-well plates at 5 x 
105 cells/ml in 1 ml RPMI with 5% FBS. Cells were challenged for 16 hr at 37° C. 
Supernatants were collected and stored at -70° C until assayed with ELISA kits for 
cytokines released. Amounts released in pg/ml were determined from a standard curve.
Flow Cytometry. After overnight treatment with D3, ceramide (C2), or LPS, THP-1 
cells were stained with FITC or phycoerythrin (PE) conjugated monoclonal antibodies to 
CD 14 epitopes including anti-CD 14/FITC (M 0-P9) from Becton-Dickinson and anti- 
CD 14/PE (MY-4) from Coulter Labs. PE-conjugated monoclonal antibodies to 
constitutively-expressed leukocyte marker, CD45, were used as a positive control stain to 
demonstrate consistent staining of samples. The staining period was 30 min at 4°C.
Cells were washed twice with staining buffer (PBS, 0.05% sodium azide, 2% FBS) and 
fixed with 1% buffered paraformaldehyde. PE and FITC conjugated isotype-matched 
negative control antibodies to myeloma proteins were used throughout to quantitate 
nonspecific background binding to target cells. Forward angle (FALS) and 90° 
(orthogonal) light scatter gating eliminated debris and dead cells from the analysis on a
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Coulter elite flow cytometer. Data represent the percentage of positively stained cells for 
a given antibody, projected beyond the cursors set on negative control histograms to 
separate positively and negatively stained cells. Cursors were set so that 1-2% o f all cells 
stained with the negative control, isotype-matched reagents were displayed as being in 
the positive region o f the histogram.
RESULTS
Growth, viability, and adherence. THP-1 cells growing between 2 -  6 x 105 cells/ml 
in RPMI with 10% FBS show a doubling time o f 72 hours (Fig. 1) and maintain a 
viability o f 98% by trypan blue exclusion. Treatment with 0.1 ug/ml LPS R595, 0.1 
pg/ml LTA (E. faecalis), or 0.1 |iM vitamin D3 for 24 hours caused temporary or partial 
adherence (Fig. 2), though cells could be gently removed from culture flasks by pipeting. 
PMA (30 ng/ml) caused significant differentiation within 24 hours to macrophage-like 
morphology, including adherence, spreading, and increases in granular inclusions. N- 
acetylceramide (C2 ceramide), a short-chain, cell-permeable ceramide, did not induce 
adherence or morphological changes. Viability remained above 95% with all o f  these 
treatments except for PMA, which dropped viability to 91% by 72 hours.
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Figure 1. THP-1 Growth Curve. THP-1 cells were maintained at 0 .3-lxl06 
cells/ml in RPMI with 10% PBS at 37°C in 5% CO2. Cells were counted by 
hemocytometer, and cells/ml were calculated to include dilutions performed when cells 
were fed and split every 3 days. Viability was determined to be > 98% by trypan blue 
exclusion. A typical experiment is shown.
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
18
120 i
O  100
o
80
©
O
XI
*¥
C
O
60 -
g> 40 
©
20 -
C2
D3
LPS
. . o
PMA
~ r -
0
“I—
24
i
48
— i—
72
— i—
96 120 144
HOURS OF TREATMENT
Figure 2. Induction of adherence in THP-l cells by various treatments. THP-1 cells 
were grown in 24-well plates in 1 ml RPMI with 10% FBS, starting at 5x10 5 cells/ml. 
Treatments were added at time 0 when all cells were in suspension. The percent of non­
adherent cells was determined every 24 hours by counting non-adherent cells by 
hemocytometer, then scraping the wells and counting total cells/ml. Treatments were at 
the following concentrations: 0.1 pg/ml LPS (R595), 0.1 pg/ml LTA (E. faecalis), 30 
ng/ml PMA, 0.1 pM vitamin D3, and 60 pM C2 ceramide. Viabilities remained above 
91% throughout the experiment.
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Lipid composition and distribution o f label in lipid pools. THP-1 cells were 
grown for 72 hours in medium containing 0.5 pCi/ml 32P (added as carrier-free H332PC>4). 
Under these conditions, the specific activity o f phosphorus (cpm/nmol phosphorus) in 
each lipid fraction was identical to the specific activity of the total cellular phosphorus. 
Total lipids were extracted from these cells as described in Materials and Methods, and 
the lipids were fractionated by thin-layer chromatography using two solvent systems. 
Individual lipids were located by autoradiography and identified by staining and co­
chromatography with known standards (Fig. 3). Table 1 summarizes the major 
phospholipids in THP-1 cells before and after a 4 hr treatment with LPS (R595 @ 100 
ng/ml). The primary phospholipid was phosphatidylcholine (PC) in both cases, but 
treatment with LPS resulted in a slight, and transient, decrease in the PC pool.
TABLE 1. Phospholipid composition of THP-1 cells/
Percentage of Total Lipidb
SM PC PI PE PA & N L
Control 3 53 13 27 6
LPS 3 49 15 27 6
a) Lipids were separated on Whatman LK6D silica gel plates using a solvent system 
consisting of chloroform-methanol-acetic acid 65:25:8.
b) SM, sphingomyelin; PC, phosphatidylcholine; PI, phosphatidylinositol; PE, 
phosphatidylethanolamine; PA, phosphatidic acid; NL, neutral lipids (unidentified). 
Experiment was run in quadruplicate, SD<1%.
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Figure 3. Chromatograph of 32P- phospholipids in THP-1 cells. Lipid extracts of 
THP-1 cells grown in medium containing 32P were separated by TLC, as described in 
Materials and Methods. Lanes 1-4 are simply varying amounts o f extract spotted on the 
plate, from 15|il -  2.5 til. The bands were scraped from the plates and counted for cpm 
released. Bands were identified by lipid standards. Values represent the counts for each 
lipid as a percent of the total. Experiments run in quadruplicate, SD<1%.
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As discussed in Chapter 1, the release of eicosanoids is an important index of 
macrophage activation, and is determined by measuring the amount o f tritium released 
from cells labeled with 3H-arachidonic acid. Cells were routinely labeled overnight (18 to 
24 hours) prior to challenge. In order to determine the distribution o f label in the lipid 
pools, THP-1 cells were treated with 0.1 pM vitamin D3, and labeled with 0.5 [iCi/ml 
3H-AA overnight. Samples were removed at intervals, mixed with unlabeled carrier 
cells, suspended in cold HBS and centrifuged. The amount o f label taken up by the cells 
was determined by counting an aliquot of the sample before and after removing the cells 
by centrifugation. The cells were washed twice with cold HBS, then suspended in 0.3% 
NaCl and extracted as described in Materials and Methods. All o f the 3H taken up by 
THP-1 cells was incorporated into the lipid pools (Fig. 4A), which suggests that little, if 
any, degradation of arachidonic acid prior to incorporation into the lipid pool occurred 
under these conditions. Figure 4B shows that label initially appeared in the PC and 
neutral lipid pools. These results suggest that PC is the most metabolically active lipid 
and that the label which is initially incorporated into the PC pool is subsequently chased 
into the PE pool. This pattern of metabolism is consistent with the hydrolysis of PC to 
diglyceride by a PC-specific phospholipase C and the subsequent conversion to both PC 
and PE.
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Figure 4. Distribution of tritium in the lipid pools. A) Kinetics of incorporation of 
label into THP-1 cells over 24 hours. The cells were cultured and extracted as described 
in the text and Materials & Methods. Values show the cpm from whole cells and their 
total lipid extracts. B) Kinetics of uptake o f 3H-AA into major phospholipid pools. 
Values for each lipid show percentages o f the total cpm in the lipid pool, and represent 
quadruplicate samples with SD<1%.
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Treatment of THP-1 cells with vitamin D3 did increase the overall uptake o f 3H-AA 
slightly. Vitamin D3 treated cells contained 3 x 10s cpm/106 cells (2.1 x 106 cpm/mg 
protein) whereas untreated cells contained 2.1 x 105 cpm/106 cells (1.3 x 106 cpm/mg 
protein). However, none o f the challenge treatments tested significantly altered overall 
uptake of 3H-AA (Fig.5).
Once incorporated into the lipid pools, 3H-AA can be released by activation o f PLA2 
by various challenges. The arachidonic acid can then be metabolized by specific 
enzymes. However, of the labeled lipid released, the major component was free 
arachidonic acid (Fig. 6). To show that, after challenge, most of the arachidonic acid was 
released via PLA2 activity as suggested in the literature (27,33), we used PLA2 inhibitor 
dexamethasone to block release o f 3H-AA (Fig. 7). It is assumed that the constitutive 
release of 3H in the supernatant is due to turnover by other enzymes or by a PLA2 which 
is not affected by dexamethasone.
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Figure 5. Uptake of 3H-AA after treatment. THP-1 cells at 6xl05/ml were pretreated 
with 0.1 pM vitamin D3 for 24 hr, and then treated for 3 hr with 100 ng/ml LPS (R595), 
50 pM C2 ceramide, 0.25 U/ml Smase (S.aureus), 20 pl/ml aCD45 2D1, or 20 pi IgGi 
(isotype matched control). The cells were washed, resuspended in fresh medium, and 
labeled with 0.5 pci/ml 3H-AA overnight. Cells were removed by centrifugation, and 
200 pi of supernatant were counted. Cell pellets were lysed by freezing in 1 ml 1% 
Triton xlOO, and 200 pi of the lysate were counted. Uptake was calculated as a percent 
o f the total cpm for each sample. Values are averages of duplicates ± range.
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Figure 6. Labeled eicosanoids released after challenge. THP-1 cells were pretreated, 
and then labeled overnight as in Fig. 4. Cells were washed and resuspended in fresh 
medium alone, or with 0.1 pg/ml LPS (R595) or 80 pM C2 ceramide for 3 hr. Cells were 
removed by centrifugation, and lipids were extracted from the supernatants as described 
in Materials and Methods. Lipids were separated into prostaglandin, peptidoleukotriene, 
and fatty acid fractions on Amprep C18 minicolumns. Values similar to those shown 
here were seen in > 3 experiments.
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Figure 7. Inhibition of 3H-AA release by dexamethasone. THP-1 cells were 
labeled as in Fig. S, washed and resuspended in fresh medium alone, medium plus 20 pM 
dexamethasone (Dex), medium plus 100 ng/ml LPS (R595), or medium plus Dex and 
LPS. After 3 hr, cells were removed by centrifugation and 200 pi of supernatants were 
counted for cpm released. Values are averages of duplicates ± range.
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CD14 expression. THP-1 cells can be differentiated to a more mature 
macrophage-like phenotype with la,25 dihydroxyvitamin D (vitamin D3). We found 
that a 24 hour treatment with 0.1 |iM D3 would induce maximal expression o f CD 14, 
while leaving the cells only slightly adherent and easy to remove from culture flasks. 
THP-1 cells were analyzed by flow cytometry for expression o f CD 14 using two different 
monoclonal antibodies: M 0-P9, which does not block LPS stimulation of THP-1 cells, 
and clone MY-4, which does block LPS stimulation (unpublished data, Ribi 
ImmunoChem). The histograms in Figure 8 show the increase in expression o f CD 14 
M 0-P 9 following treatment with vitamin D3. Both the percentage of cells staining 
positive in the gated population (the histogram peak), and the mean channel fluorescence 
(location of the peak on the X axis) increased by at least 50% for both anti-CD 14 
antibodies within 18 hours after treatment with D3. However, neither % positive nor 
mean channel fluorescence was significantly altered by LPS, ML A, or ceramide (Table 
2)-
Consistent with our findings, treatment with vitamin D3 has been reported to 
increase sensitivity o f THP-1 cells to LPS (57,69,98), presumably due to the expression 
o f CD 14. Figure 9 shows that pretreatment with vitamin D3 also increased THP-1 cell 
sensitivity to ceramide for the release of arachidonic acid metabolites. It is unlikely that 
expression of CD14 is involved in ceramide signaling, but it is very possible that D3 up- 
regulates other signal components that have not yet been determined.
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Figure 8. Demonstration by flow cytometry of increased expression of CD14 after 
D3 trea tm en t THP-1 cells, untreated (top) or treated (bottom) with vitamin D3 for 18 
hours, were analyzed for expression of CD14 using anti-CD14 M0-P9. Cells were 
stained and analyzed by flow cytometry as described in Materials and Methods. A) 
Gated population, B) anti-CDf4/F!TC, C) anti-CD45/PE (Positive control).
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TABLE 2
Surface expression of CD 14 measured by flow cytometry after treatment with LPS, C2 
ceramide, or vitamin D3.*
TREATMENT: Control LPS C2 MLA D3
aCD14(M0-P9) 5.9b 4.9 5.5 3.9 82.2
8.4C 7.1 7.6 7.2 15.4
aCD14 (MY-4) 52.5 67.5 56.7 63.1 97.8
4.4 4.4 4.0 4.0 52.5
aCD45 (2D1) 98.8 97.8 98.8 98.9 95.7
14.6 15.6 12.5 16.5 9.5
a) THP-1 cells were treated for 18 hr with medium only, 100 ng/ml LPS (R595), 40 pM 
C2 ceramide, 100 ng/ml MLA, or 0.1 pM vitamin D3. Cells were then stained and 
analyzed by flow cytometry as in Materials and Methods.
b) Percent of gated (90% vs FALS) cells staining positive
c) Mean channel fluorescence -  4 decade logarithmic range
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Figure 9. Increased sensitivity of THP-1 cells after D3 pretreatment. THP-1 cells 
were treated with 0.1 |iM vitamin D3 for the indicated times, labeled with 3H-AA and 
challenged with medium only, 1 ng/ml LPS (R595), or 100 pM C2 ceramide for 4 hr. 
200 fjl o f post-challenge supernatants were counted. Values are averages of duplicate 
samples ± range, and results are representative of 2 experiments.
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DISCUSSION AND CONCLUSION
THP-1 cells have proven to be a good model for our studies as long as they are 
cultured at consistently low density (2 - 6 x 10s cells/ml) and maintained for about 20 
passages before starting a fresh batch from frozen stocks. Vitamin D3 increased 3H-AA 
uptake, CD 14 expression, and sensitivity to challenge, making them responsive for our 
assays (Fig 8 & 9, Table 2). Studies have shown that in THP-1 cells, LPS induced 
hydrolysis of phosphatidylcholine (PC), but did not affect lipid pool labeling or the 
hydrolysis of phosphatidylethanolamine (PE) or phosphatidylinositol (PI) (18). We 
wanted to confirm this result to provide evidence that our treatments did not affect pool 
labeling. Because PC is the major substrate for PLA2, altered pool labeling would 
confuse our results. Analysis o f lipid extracts confirmed that the major phospholipids in 
THP-1 cells are PC and PE, and that these pools contained the majority o f label following 
incubation with 3H-AA (Figs. 3 & 4). Label in the PE and PI fractions remained constant 
or increased slightly after 1 0 -1 5  hours of incubation in the presence o f label, whereas 
label in the PC pool dropped off. This suggests that the PC is the most active in terms of 
turn-over.
None of our challenge treatments affected viability, CD 14 expression, or uptake of 
3H-AA (Figs 2 & 5, Table 2). Therefore, these parameters could be ruled out as factors 
that might have affected sensitivity o f the cells to challenge, and therefore the cpm 
released from treated cells.
PMA acts as a diacylglycerol analog, activating cells downstream from receptor- 
mediated signaling. It was used as a negative control for experiments assuming a
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receptor-dependent mechanism (Chapter 5). It was not used as a differentiation inducer 
due to the high degree of adherence it caused (Fig.2), the mild cytotoxicity seen, and the 
fact that it does not increase CD14 expression (27).
Since free arachidonic acid was the major component of total labeled lipid released 
(Fig. 6), changes in the metabolism of a portion of the free fatty acid to prostaglandins or 
leukotrienes might not be apparent from simply measuring 3H-AA release. It was 
therefore important for the rest of the studies to check for different patterns of signaling 
induced by various challenges, by measuring specific eicosanoids. Inhibition of release 
with dexamethasone, a phospholipase A2 inhibitor, showed that most of the arachidonic 
acid released from activated macrophages was due to PLA2 activation (Fig. 7).
Most of the experiments for this thesis were performed using THP-1 cells.
However, we frequently repeated tests using mouse peritoneal exudate cells (PEC) or 
RAW274.6 murine macrophages, and found that the mouse cells responded similarly in 
most cases. Experimental data demonstrating this are presented in subsequent chapters.
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CHAPTER 3
ACTIVATION AND DESENSITIZATION OF MACROPHAGES BY 
BACTERIAL AMPHIPHILES
Introduction
Septic shock is the pathophysiological response to systemic infections by Gram 
negative or Gram positive bacteria. The response includes an exaggerated systemic 
inflammatory response, hypotension, intravascular clotting, multiple organ failure, and 
death. The biologically active molecules that appear to be involved in the activation of 
this response are amphiphiles located in the outer membrane or wall of these bacteria, 
including lipopolysaccharride (LPS) and lipoteichoic acids (LTA), respectively. In Gram 
negative septic shock, the majority of the toxicity is attributed to the lipid A component 
of LPS. LTA is 100 to 1000-fold less potent than LPS, and does not appear to be able to 
induce septic shock by itself. There is some evidence that septic shock caused by Gram 
positive bacteria results from the combined effects of LTA and peptidoglycan (22). 
Nevertheless, LTA has been shown to bind similar receptors as LPS (19,25,38), activate 
several common pathways (72), and is able to desensitize cells to subsequent challenge 
with LPS (16).
Although structurally different in many ways, both LPS and LTA are anionic
polymers containing lipid, carbohydrate, and phosphorus. Intriguingly, both have also
been shown to vary considerably in potency depending on the source organism
(10,16,38,65), which suggests that minor variations in the molecular structure affect the
34
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ability o f the host to recognize and respond to the amphiphiles. Studies on the molecular 
and supra-molecular structure of many forms of LPS have shown that variations in acyl 
chain length and fluidity, acylation patterns, saccharide components, and phosphate 
residues all affect aggregate formation, and the toxicity and immunostimulatory effects of 
LPS preparations (14,40). Similarly, the charge ratios o f the monomer, the acyl chains, 
and the size o f the polyglycerophosphate chain all affect micelle formation o f LTA and 
the binding of LTA to cellular receptors (38). This suggests that immune cells recognize 
and respond differentially not only to the molecules themselves, but to these unique 
aggregates, so that the signal transduction initiated at the cell surface varies to produce a 
wide range o f responses. For example, when LPS from the rough mutant of Salmonella 
minnesota R595 is modified to monophosphoryl lipid A (MLA), toxicity is significantly 
reduced but the immunostimulatory activity is maintained (40). A relationship between 
structures of various LTAs and their potencies has not been found. In fact, two similar 
LTAs have been shown to have very different potencies in terms of activation of 
arachidonic acid metabolism (16).
The potent toxic and immunostimulatory properties of LPS and other bacterial 
amphiphiles result from lipid and protein mediators released primarily from activated 
macrophages. It is not clear whether these differential effects result from differences in 
the amount o f all mediators released or from a selective increase or reduction of 
particular mediators. The phenomenon of desensitization also appears to occur just 
downstream from binding and does not appear to involve down-regulation of any LPS- 
binding surface proteins (28). The ability of LPS preparations to desensitize cells has
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been considered a possible mechanism to exploit in the treatment and/or prevention of 
septic shock. Preliminary studies in animal models have shown that pretreatment with 
low levels o f LPS, especially the less toxic forms, can be protective (3,40). However, in 
vitro studies are necessary to determine the mechanism o f desensitization before the 
feasibility o f further in vivo testing would be justified. Because the release o f eicosanoids 
is critical in the development of inflammatory reactions, it was important to begin to 
characterize the release of arachidonic acid metabolites following treatment with various 
bacterial amphiphiles as a baseline for studies on pyrogenicity and the impact o f 
monomeric and supramolecular structures on potency and toxicity. The preliminary work 
reported here has led to further investigations still underway through a contract with Ribi 
ImmunoChem Research.
In this study, we have compared the response of THP-1 cells to various bacterial 
amphiphiles, including LPS RS95 and its derivatives, monophosphoryl lipid A (MLA) 
and diphosphoryl lipid A (DPL); smooth LPS from S. abortus, and LTA (E. faecalis) as 
measured by the release of arachidonic acid metabolites and pro-inflammatory cytokines. 
We also demonstrate the ability of both MLA and LTA to desensitize THP-1 cells to 
subsequent challenge with LPS, and this was correlated with the release of a putative 
autocrine factor, PGE2. Experiments repeated using mouse peritoneal cells (PEC) or 
RAW264.7 murine macrophages showed similar results.
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MATERIALS AND METHODS 
Amphiphiles and reagents. All LPS and lipid A preparations were provided by 
Ribi ImmunoChem Research (Hamilton, MT). Stock solutions o f amphiphiles at 1000 
|ig/ml were kept at 4° C in 0.1% TEA. Vitamin D3 ( la , 25 dihydroxyvitamin D) was 
purchased from Calbiochem (LaJolla CA). LTA from S. faecalis, PMA, and 2- 
mercaptoethanol were obtained from Sigma. Quantikine ELISA kits for tumor necrosis 
factor alpha (TNFa), IL-1, and IL-8 were purchased from R&D Systems, and EIA kits 
for eicosanoids were from Cayman Chemical (Ann Arbor MI). [3H]-arachidonic acid 
was purchased from American Radiolabeled Chemical Co. (St. Louis, MO).
Cell Culture. THP-1 cells from ATCC were cultured in RPMI from Mediatech, 
supplemented with 10% Hyclone fetal bovine serum (FBS) and 2 x 10'5 M 2- 
mercaptoethanol at 37° C in a 5% C 02 incubator. Cells were maintained between 2.5 x 
10s and 1 x 106 cells/ml. Prior to experiments, cells were incubated overnight with a 
maturation agent, either 10*7 M vitamin D3 or 2nM PMA. Although loosely adherent, 
cells could be removed by pipeting or gentle scraping. RAW 264.7 cells from ATCC 
were maintained as adherent monolayers in Dulbecco’s Modified Eagle’s medium 
(Sigma) supplemented with 10% FBS. Peritoneal exudate cells were harvested by 
peritoneal lavage from Swiss Webster mice as previously described (16). After a 2 hour 
adherence period, non-adherent cells were removed by washing with warmed RPMI. 
Challenge experiments
Eicosanoid release. RAW 264.7, PEC, or differentiated THP-1 cells were labeled 
overnight with 0.5 pC/ml 3H-AA (specific activity = 200 Ci/mmole) in RPMI with 10%
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FBS, then washed three times with warmed RPMI. Cells were then gently removed from 
flasks and plated in 24-well plates at approximately 1.5 x 106 cells/well in 0.5 ml RPMI. 
Challenge concentrations (2x) were added, 0.5 ml/well in RPMI with 4% FBS. Plates 
were incubated for 2 hr at 37° C. Supernatants were transferred to microfuge tubes and 
spun at 3000 rpm for 3 min to remove any cells. 200 pi of the cell-free supernatants were 
counted in a Beckman scintillation spectrometer. PG and LT fractions were determined 
by separation of radiolabeled lipids released from treated cells on Cl 8 minicolumns using 
solvent systems discussed in Chapter 2 (Materials and Methods), or by EIA (Cayman 
Chemical).
Cytokine release. Differentiated THP-1 cells were plated in 24-well plates at 5 x 
10s cells/ml in 1 ml RPMI with 5% FBS. Cells were challenged for 16 hr at 37° C. 
Supernatants were collected and stored at -70° C until assayed with ELISA kits for 
cytokines released. Amounts released in pg/ml were determined from a standard curve. 
Desensitization experiments
Eicosanoid release. Cells were pretreated with MLA or LTA at various 
concentrations in medium with 10% FBS for 2 hr prior to the labeling period. Cells were 
washed twice with warm medium to remove pretreatment. Labeling and challenge 
periods were done as in challenge experiments.
T N Fa assay. Cells were pretreated with MLA for 18 hr and were not washed prior to 
challenge. Cells were then challenged with LPS R595 at 10 ng/ml for 6 hr. Supernatants 
were assayed as in challenge experiments.
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RESULTS
Arachidonic acid release from THP-1 and RAW264.7 cells by bacterial 
amphiphiles. The various challenges showed a range of potencies with respect to their 
ability to activate arachidonic acid metabolism in THP-1 cells, with the most dramatic 
difference between LPS R595 and MLA (Figs. 1 and 2). THP-1 cells required a 
thousand-fold higher concentration o f MLA to release the amount o f eicosanoids released 
by LPS R595. A 1000-fold higher concentration of MLA caused only 50% o f the levels 
o f cytokines released by LPS R595 (Fig. 3).
Figure 4 shows a significant difference in the potencies o f two MLA preparations, 
MPL (MLA solubilized in 1% TEA) and MPL-s (MLA solubilized in 10% ethanol), with 
MPL-s approximately 70% more active for release o f arachidonic acid.
In RAW264.7 murine macrophage cells, LPS R595 and E. faecalis LTA showed 
similar potencies (Fig. 5).
Prostaglandin/Leukotriene molar ratios released after challenge. O f the 
eicosanoids assayed, LPS, LTA and MLA all induced primarily prostaglandins, resulting 
in relatively high PG/LT ratios compared to amounts released from untreated cells (Fig.
6). In the experiment shown, the ratio of PGE 2/LTC4 from MPL-s is considerably higher 
than the other amphiphiles. In other experiments, this ratio tended to slightly higher than 
the others, but not as dramatic as shown here.
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Figure 1 and 2. The effect of bacterial amphiphiles on 3H-AA release. Differentiated 
THP-1 cells were labeled overnight with O.S jiC/ml 3H-arachidonic acid in RPMI with 
10% FBS. Cells were washed and plated in a 24-well plate at l.SxlO6 cells/ml and 
challenged with concentrations of LPS R595, MLA, DPL, LPS (S. abortus), and LTA (E 
.faecalis) for 2 hours. 200 |il of supernatants were counted for cpm released. Relative 
activities were calculated based on labeled metabolites released relative to cells-only 
control. Points are averages of duplicates.
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Figure 3. Effect of bacterial amphiphiles on cytokine release. Differentiated THP-1 
cells were plated in 24-well plates at lxlO6 cells/ml and challenged with LPS R595 and 
MLA in RPMI with 5% FBS for 18 hours. Cytokines released were measured by ELISA 
and converted to pg/ml from a standard curve. Values represent amounts released by 
MLA as percents of the amount released by LPS R59S at 10 ng/ml. Points are averages 
o f duplicates.
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Figure 4. Difference in potency due to solute: MPL vs MPL-s. Differentiated THP-1 
cells were treated as in Fig. 3, and challenged with either MPL or MPL-s for 2 hours.
200 pi of cell-free supernatants from each sample were counted for cpm released. Values 
are averages o f duplicates, ± range.
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Figure 5. Effect of LPS and LTA on arachidonic acid released from RAW264.7 
m urine macrophages. RAW264.7 cells were plated in 24-well plates at lxlO6 cells/ml 
and allowed to adhere. They were labeled overnight with 3H-AA, and then gently 
washed with warm RPMI. The cells were challenged with LPS R595 or LTA (.E 
faecalis) for 2 hr. 200 pi of supernatants were counted for cpm released. Values are the 
averages o f duplicates ± range.
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Figure 6. PGE2/LTC4 ratios measured from THP-1 cells challenged with LPS, 
MLA, DPL, or LTA. Differentiated THP-1 cells were plated in 24-well plates at 5xl05 
cells/well in RPMI with 5% FBS, and challenged in 1 mi/well with LPS R595, MLA, 
DPL, or LTA (Efaecalis) at 1000 ng/ml. Supernatants were assayed for specific 
eicosanoids by El A as per manufacturer’s instructions, and converted to pg/ml from a 
standard curve. Molar ratios were calculated for PGE2/LTC4. Values are the averages of 
duplicates.
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Desensitization of macrophages by bacterial amphiphiles. MLA has been 
shown to protect mice and humans from the lethal effects of LPS (3,40). Our data show 
that a 18 hr pretreatment with MLA followed by LPS R595 challenge reduced TNFa 
release from THP-1 cells by up to 92% (Fig. 7).
10 100 1000 10000 
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Figure 7. Desensitization by MLA to LPS challenge: TN Fa release. Differentiated 
THP-1 cells were pretreated with 100 ng/ml MLA for 18 hours and then challenged with 
10 ng/ml LPS R595 for 6 hours. Supernatants were collected stored at -70°C until 
assayed by ELISA for TNFa, using Quantikine Kits following manufacturer’s 
instructions. The % inhibition was calculated based on the amount of TNF released by 
10 ng/ml LPS without pretreatment with MLA.
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A 2-3 hour pretreatment with MLA followed by washing and labeling o f the cells, 
reduced eicosanoid release over 50%, even 18 hours after removal o f the MLA (Fig. 8).
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Figure 8. Desensitization by MLA to LPS challenge: 3H-AA release. Differentiated 
THP-1 cells were pretreated with MLA at 0, 1, and 10 pg/ml for 2 hours, then washed 
and labeled overnight as in Fig. 1. Cells were washed 3x and challenged for 3 hours with 
LPS R595 (1 ng/ml). 200 pi of supernatant samples were collected and counted for cpm 
released. Values are averages of duplicates.
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Pretreatment for 2-3 hours with LTA also desensitized cells to subsequent 
challenge with LPS. This was shown in RAW264.7 cells (Fig. 9), and also in THP-1 and 
mouse PECs (data not shown).
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Figure 9. Desensitization of RAW cells by LTA to LPS challenge: 3 H-AA release.
RAW264.7 mouse macrophages were plated at 1>:106 cells/ml in 24-well plates and 
allowed to adhere for 2 hr. They were pretreated with LPS (R595) or LTA (E. faecalis) 
for 2 hours at concentrations shown, then washed and labeled overnight as in Fig. 1. The 
cells were then washed and challenged with LPS R595 at 1 ng/ml for 2 hours. Values 
cpm above control and are averages of duplicates. ± range.
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Challenge of THP-1 cells with a vortexed mixture of MPL and LPS R595 at a 10:1 
mass ratio resulted in a dramatic attenuation o f the release o f eicosanoids seen with LPS 
alone (Fig. 10).
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Figure 10. Effect of LPS/MPL mixed challenge on 3H-AA release. THP-1 cells were 
labeled as in Fig. 1 and challenged with LPS R595 and MPL for 2 hr. Mixed challenge 
consisted of dilutions of MPL and LPS vortexed together in a 10:1 mass ratio 
(MPL:LPS). When graphing the mixed challenge, the MPL concentrations were used to 
plot points. Values represent the amount of label in 200 til o f supernatant samples 
counted for cpm released, and are averages of duplicates, ± range.
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However, if MPL was added 1 hour prior to the addition of LPS (10:1 mass ratio), the 
attenuation of LPS potency was not seen (Fig. 11).
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Figure 11. MPL/LPS mixed challenge, adding MPL prior to LPS to allow binding 
time. THP-1 cells were challenged as in Fig. 10. However, for one set of data, the MPL 
and LPS were not vortexed together. Instead, the MPL was added 1 hr prior to addition 
of LPS. Again, for mixed challenges, MPL concentrations are shown. Values are 
averages of duplicate 200 pi samples of cell-free supernatants, counted for cpm released.
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DISCUSSION
It is widely accepted that the biologically active constituent o f lipopolysaccharide 
is lipid A, and it is strongly implicated as the cause of endotoxic shock. However, studies 
have shown that the potency of LPS molecules can be modulated by the configuration o f 
the polysaccharide portion (35,65) or the acyl chains (14). Lipoteichoic acids appear to 
be at least partially responsible for a similar condition called Gram positive septic shock, 
and they also show variations in potency when derived from different Gram positive 
organisms (10,16). The purpose of this study was to quantify lipid mediators released 
from macrophages challenged or desensitized with different LPS and LTA preparations. 
These data would provide a basis for developing hypotheses regarding the mechanisms 
behind the variable potencies, and the desensitization phenomenon. The results reported 
here are some of the few comparative studies of eicosanoids released from human THP-1 
cells following challenge with bacterial amphiphiles.
The relative potencies of the various amphiphiles were LPS R595 > DPL > S. 
abortus LPS and E. faecalis LTA >MLA. It is not clear what events occur at the cell 
surface to attenuate the signal transduction events. LPS, LTA (19,45,59), and MLA 
(unpublished data) have all been shown to bind the putative receptor, CD 14. CD14 has 
been described as a “pattern recognition” receptor (75), meaning that the binding requires 
a particular spatial arrangement o f charges. It also has been shown to require monomeric 
binding so that aggregates such as micelles are quite inactive (85). With this information, 
it is possible to visualize several reasons for the variations in activity o f  the amphiphiles 
that bind CD14. First, the stability of the micelle will affect the rate at which conversion
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to monomers occurs. In aqueous solution, less stable aggregates will produce a higher 
concentration o f monomers available for binding to CD 14, and these molecules would 
most likely show higher potency simply due to availability. Structural variations o f the 
fatty acids (length, fluidity), the hydrophilic core cross-sectional area, and the charge 
density of the polar side groups will all affect micelle stability and overall supramolecular 
configurations. Lipopolysaccharide binding protein (LBP) has been shown to bind LPS 
monomers and facilitate binding to CD 14. This dramatically increases cell 
responsiveness to LPS. LTA has also been shown to be much more potent in the 
presence o f serum, suggesting that a serum protein may play a similar role for delivery of 
these amphiphiles (16). Therefore, structural features of the particular amphiphile in the 
micelle may also affect the ability o f LBP (or other serum protein) to bind and disperse 
the micelle for delivery to CD 14.
Second, slight alterations in the charge pattern of the ligand’s binding site may 
strongly affect its affinity for CD 14. This has been shown to be true with the binding of 
various LTAs to the scavenger receptor on macrophages, which is another pattern 
recognition receptor (38). Third, there is increasing evidence that CD 14 is more of a 
delivery vehicle than a signal transducer, permitting internalization of the ligand via 
vesicle formation (97). Activation would then occur after binding to another receptor. 
Deacylated, biologically inactive lipid A derivatives have been shown to compete for 
binding sites on LBP and CD14, and block LPS responsiveness (56,57). This suggests 
that even inactive forms of LPS bind CD 14, but do not transduce the activation signal. 
Structural variations would therefore affect binding to subsequent receptors so that
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various amphiphiles might simply be less active due to lower affinity, might serve as an 
antagonist, or might activate different pathways resulting in different patterns o f 
mediators released.
The data reported here combined with studies o f the supramolecular structure of 
various amphiphiles support the micelle stability model of potency. All o f these 
amphiphiles were capable o f desensitizing the cells to subsequent challenge. This 
suggests common pathways involved in that regulatory mechanism. Also, all o f  the 
amphiphiies tested activated similar ratios of PGE2 /LTC4, suggesting that the same 
pathways were activated. In another study with mouse macrophages, smooth and rough 
LPS, LTA, and MLA all caused the release of similar PGE2/LTC4 ratios of approximately 
10:1 (16). Interestingly, Luderitz, et al. (65) showed that lipopolysaccharides o f rough 
mutant enterobacteria induced both LTC4 and PGE2 from mouse peritoneal macrophages, 
whereas wildtype (smooth) LPS preparations caused the release of PGE2 but not LTC4. 
The reasons for these different results are unknown.
Correlations between monomer structures and potencies have not been found for 
LPS or LTA (10,78). However, Brandenburg, et al. (14) showed that variations in acyl 
and saccharide structure combine to produce unique three-dimensional aggregates of the 
lipid A derivatives in aqueous environments, and that the ability of the molecules in a 
sample to adopt non-lamellar inverted structures is closely correlated with endotoxic 
potency (Fig. 12). Inactive forms o f LPS, however, form lamellar structures including 
micelles. However, since several different factors affect aggregate formation, it is 
unlikely that potency is related to any single monomeric structure. More likely, a set of
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conditions yield a configuration that forms a particular type of aggregate. It is not known 
whether the toxicity is due to the aggregation itself or to the configuration that yields the 
aggregate above a certain concentration. It is possible that the critical factor is the 
stability of the aggregate and therefore the availability o f monomers for binding to target 
receptors.
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Figure 12. TOP: The relationship between molecular conformation and subsequent 
supramolecular structures. From Seydel, et al., 1993(82). Phase behavior, 
supramolecular structure, and molecular conformation oflipopolysaccharide.
BOTTOM: The relationship between supramolecular structure and toxicity. From 
Brandenburg, et al., 1993(14). Influence of the supramolecular structure of free lipid A 
on its biological activity.
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LTA from E. faecalis is o f the Type I structure, consisting o f an unbranched 1,3- 
linked polyglycerophosphate chain linked to a membrane diacyigiyceroglycolipid 
containing one (20) or two fatty acid tails (38) (Figure 13). This type lacks compensatory 
charges for the heavily negatively charged polyglyceroposphate residues, and includes 
some of the more active LTAs (eg. LTA from E. faecalis, S. aureus) (16). Since the 
highly charged outer rim of the Type I LTA micelle would tend to make the micelle less 
stable, this suggests that micellar stability could be a factor in LTA potency as well. The 
critical micellar concentration (CMC) for LTA has been reported as 1-10 ng/ml (103) and 
28-60 ng/ml (20). Despite this range of reported data, LTA clearly requires relatively 
high concentrations of monomers before micelles begin to form, possibly due to the size 
of the hydrophilic portion of the molecule. Our data show that LTA (E. faecalis) 
activates arachidonic acid metabolism well below CMC, as low as 10 ng/ml, and levels 
out above 10 ng/ml (unpublished data). This is consistent with the idea that as micelles 
form, the concentration of monomers in solution remains constant, in a dynamic 
equilibrium with molecules in aggregate form.
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Figure 13. Type 1 Lipoteichoic Acid.
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The micellar stability model is also supported by the fact that two preparations of 
MLA, differing only in their solutes, have shown significant differences in potencies for 
arachidonic acid release. MLA in 1% TEA (MPL) was much less active than MLA 
solubilized in ethanol (MPL-S) (Fig. 14). MPL-S has been shown to have better 
solubility than MPL. The MLA used in these experiments was prepared from R595 LPS 
and lacks the phosphate group and the 3’ acyl chain on the reducing glucosamine.
o
o k d / o
Figure 14. Monophosphoryl Lipid A (MLA, MPL)
MLA has been shown to form cubic or lamellar structures due to the lower number of 
fatty acids and the reduced charge density o f the glucosamine backbone (82). This type 
o f aggregate is correlated with reduced biological activity (14) and might explain some of 
the reduced potency o f this lipid A preparation for arachidonic acid release. R595 LPS is 
prepared from the deep rough mutant o f Salmonella minnesota R595 in which the LPS 
lacks both O side chain and core polysaccharide (Figure IS). R59S has a cone-shaped 
monomeric configuration which strongly favors non-lamellar (cubic) supramolecular 
aggregates (82). Its relatively high activity is consistent with reported correlations 
between non-lamellar structures and toxicity (14,78). The non-lamellar
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Figure 15. ReLPS from S. minnesota.
structures are relatively unstable in aqueous solution due to the exposure o f the 
hydrophobic tails to the aqueous solute. The molecules involved may therefore be more 
potent due to the ease of transfer from the aggregate to CD 14.
Diphosphoryl lipid A (DPL) is prepared by the removal of the entire inner core and 
KDO from R595 LPS (Figure 16). This monomer tends to adopt non-lamellar structures 
similar to those o f ReLPS. Our data on DPL activation of arachidonic acid release (Fig. 
2) support earlier work showing DPL to be 10-100 fold more lethal and pyrogenic than 
MLA in mouse studies (14).
Figure 16. Diphosphoryl Lipid A (DPL).
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The moderate response to LPS from S. abortus (Fig. 2) is interesting since its 
structure is o f a smooth LPS, containing complete core polysaccharide and O side chain. 
Micelles o f highly glycosylated lipids can vary considerably in stability based on the 
lengths o f these sugar residues. The overall trend is toward more lamellar structures with 
increasing sugar residues (14). Therefore, our data are consistent with a more lamellar 
structure for smooth LPS, and therefore less activity.
When MLA and LPS were added together in a 10:1 ratio to challenge THP-1 cells, 
response was significantly reduced compared to challenge with LPS alone (Fig. 10). One 
interpretation of these results is that the MLA competed for binding and blocked 
activation of the cells by the more active LPS. Other studies have shown that several 
lipid A derivatives compete for binding at LPS binding sites (56,57). However, these 
same studies showed that the blockage of activation occurred at a site distinct from the 
binding event (56). If MLA was not actually mixed with the LPS, but was added first and 
allowed time to bind to the cells, the attenuating affect was not seen (Fig. 11). It seems 
possible that combining MLA with LPS could alter the resulting mixed aggregate from a 
non-lamellar aggregate to one that is more lamellar. Another possibility is that lipid A 
derivatives block signaling by binding to receptors by the exposed core polysaccharide 
while still in an aggregated form, but do not signal due to the unavailability o f the acyl 
chains. Rietschel, et al. (79) have shown that the core polysaccharide is critical for 
binding, whereas the acyl chains activate signaling. However, we have shown that 
prebinding of MLA followed by LPS challenge did not inhibit the activation by LPS.
This argues against a competitive binding type of inhibition (Fig.9).
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Our results show that THP-1 cells treated with MLA, which has low toxicity, 
released significantly lower amounts of all mediators measured, including labeled 
arachidonic acid (Fig. 1), TNFa, II-1, and IL-6 (Fig. 3). The only product shown to 
increase following treatment with MLA was prostaglandin, which also increased 
following activation with LPS or LTA (Fig. 6). Reduction o f pro-inflammatory 
cytokines with concomitant increase in PGE2 may be part o f the reason MLA retains 
immunostimulatory properties and the ability to desensitize cells, yet is not endotoxic. 
Prostaglandin E2 has been implicated in autocrine down-regulation of nitric oxide 
synthase and tumoricidal activity in mouse macrophages (76), and of TNF in a human 
monocytic cell line (41). It is possible that it is the release of prostaglandin that allows 
these agents to desensitize the cells to subsequent challenge.
This limited study on potencies of bacterial amphiphiles is not conclusive regarding 
a predictable model based on monomeric and/or supramolecular structures. However, it 
provides some evidence supporting the hypothesis that aggregate stability may play a role 
in the variable potencies for the release of arachidonic acid metabolites and pro- 
inflammatory cytokines, and therefore in vivo toxicity. These studies also suggest that all 
of these amphiphiles share similar pathways in terms o f the release o f specific 
eicosanoids, and in the phenomenon of desensitization.
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CHAPTER 4
A Comparison of the Effects of LPS and Ceramide on Arachidonic Acid
Metabolism in THP-1 Monocytic Cells
Introduction
Recent advances in the study of sphingolipids as mediators of signal transduction 
have provided new clues to the complexities of macrophage activation. In 1989, Okazaki 
showed that vitamin D3 treatment ofHL-60 myeloid leukemia cells caused the hydrolysis 
o f sphingomyelin, resulting in the release of ceramide with subsequent differentiation of 
the cells and growth arrest (73). Since then, many studies have explored the role of 
ceramide as a second messenger in different cell types. Ceramide released through the 
neutral sphingomyelinase cycle (Figure 1) has been shown to transduce signaling in 
immune cells activated with tumor necrosis factor (TNFa) and interleukin 1 (6,54).
Sphingomyelin
OPOCHaCHsN (CHa ̂
D A G - ^ Glyewo'  LW' U  pn«pnoiipids
CHOUNE-P
Glyco-
sphingaipids Ceramide
CĤX
Figure 1. The Sphingomyelinase Cycle. Enzyme I = Sphingomyelinase. Enzyme II 
Phosphocholine transferase. (From Ballou, 1996)
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Some o f the biological effects of ceramide in immune cells include cell differentiation, 
cell cycle arrest, and in some circumstances, apoptosis. These effects are mimicked by 
cell-permeable ceramides such as N-acetylsphingosine (C2 ceramide, Figure 2) (11,54). 
There is some evidence that exogenous bacterial sphingomyelinase (SMase) may mimic 
ceramide signaling by releasing endogenous ceramide, but a recent study suggests that 
the ceramide released is from a distinct pool that is not involved in these signaling 
pathways (109).
OH
CERAMIDE
.CH2OH
C2-CERAMIDE
Figure 2. Ceramide and C2 ceramide, a short-chain, cell permeable analog.
Research has shown that the biological response of cells activated with LPS is 
similar to the response of cells treated with TNFa or IL-1. However, no accumulation of 
ceramide was observed (52). This, along with the structural similarity between ceramide 
and the reducing glucosamine of the lipid A moiety of LPS, led Wright and coworkers 
(52,107) to suggest that LPS may exert its effects through mimicry of ceramide (Fig. 3).
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Figure 3. Structural similarity between ceramide and the acylated reducing 
glucosamine of Lipid A. (From Wright, 1995)
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A better understanding o f how LPS exerts its effects on immune cells is 
important due to its role as the primary mediator of septic shock. Septic, or endotoxic, 
shock is characterized by severe immune dysfunction and can lead to circulatory system 
compromise, organ failure, and death (5,13). Most of the toxicity of LPS has been traced 
to the lipid A portion of the molecule (79), and macrophages appear to be critical players 
in the immune dysfunction that leads to systemic failure (30).
Eicosanoids are biologically active arachidonic acid metabolites that are rapidly 
released from macrophages following activation with various agents such as LPS and 
phorbol myristate acetate (PMA). Free arachidonic acid is released from lipid pools by 
the activation of phospholipase A2 (PLA2), and is then metabolized to the various 
eicosanoids by specific enzymes. Two o f the major eicosanoids released from 
macrophages are prostaglandins (cyclo-oxygenase pathway) and peptidyl-leukotrienes 
(lipoxygenase pathway) (31,33,48,105). The ratio of these two lipid families appears to 
be important in the regulation o f the immune response (48,100,105). I f  LPS mimics the 
second messenger function o f ceramide, then exogenous ceramide should cause the 
release of similar combinations o f eicosanoids. LPS increases both PLA2 and cyclo- 
oxygenase activities, but not 5-lipoxygenase in mouse macrophages (33,76,105), and 
human monocytes (31). Less is known about the effects of ceramide on arachidonic acid 
metabolism. Hayakawa, et al. (46) showed that exogenous ceramide activated 
transcription of PLA2 and cyclo-oxygenase 2 in L929 cells. In HL-60 cells, it appears 
that the release of arachidonic acid is part of the signal transduction pathways via the 
TNFa and IL-1 receptors that activate the sphingomyelinase cycle (51), and therefore
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occurs prior to the release of endogenous ceramide. There is also some evidence that 
TNF may activate two pathways via different lipid pools, one activating PLA2 and the 
other leading to ceramide generation and NF-kB translocation (63,80,104). Clearly, the 
signal transduction events that lead to eicosanoid production in response to LPS or the 
sphingomyelinase pathway are complex and their interrelationships remain to be 
elucidated.
LPS has been shown to desensitize macrophages to subsequent challenge with 
LPS (96) so that the release of eicosanoids and cytokines is suppressed. If LPS simply 
mimics ceramide, ceramide should show similar effects. Barber, et al. (7) have recently 
shown that although exogenous SMase did not desensitize murine peritoneal 
macrophages to subsequent challenge with LPS, LPS did desensitize the cells to 
challenge with exogenous SMase as measured by the release of TNFa. They suggested 
that LPS appears to share some signaling roles with ceramide, but that the signaling 
pathways must diverge to produce these results. Their work was done using exogenous 
sphingomyelinase from S. aureus under the assumption that it would release endogenous 
ceramide in a manner similar to activation of endogenous SMase. However, Zhang, et al. 
(109) recently showed that exogenous SMase is unable to mimic the effects of ceramide 
generated by endogenous neutral SMase or by cell-permeable ceramides. It will be very 
important to determine which treatments most closely mimic endogenous ceramide, 
before the mimicry of ceramide by LPS can be elucidated in terms o f signaling pathways.
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In order to address these questions regarding LPS mimicry of ceramide, we 
compared the effects of exogenous N-acetylsphingosine (C2 ceramide) and 
sphingomyelinase (S. aureus) with those o f LPS on the release o f arachidonic acid 
metabolites from THP-1 monocytic cells, and the ability of these agents to induce a state 
of tolerance to subsequent challenge.
MATERIALS AND METHODS 
Materials. THP-1 cells were purchased from American Type Culture Collection 
(Rockville MD). Cellgro R PM I1640 was from Mediatech (Herndon VA), and defined 
fetal bovine serum (FBS) was purchased from HyClone (Logan UT). Purified LPS R595 
from S. minnesota was provided by Ribi Immunochem Research (Hamilton MT).
Tritiated arachidonic acid was purchased from American Radiolabeled Chemical Co. (St. 
Louis MO). Vitamin D3 ( la , 25 dihydroxyvitamin D) and dihydroceramide were 
purchased from Calbiochem (LaJolla CA). Monoclonal antibodies for flow cytometry 
were purchased from Becton-Dickinson Immunocytometry Systems (San Jose CA) and 
Coulter Laboratories. Enzyme Immunoassay kits were obtained from Cayman Chemical 
Co. (Ann Arbor MI). All other chemicals were from Sigma Chemical (St. Louis MO).
Cell Culture. Cells were grown in RPMI supplemented with 10% FBS, 100 U 
pennicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine, and maintained between 2 -  
6 x 10s cells/ml at 37°C with 5% CO2. Viability remained above 97% throughout the 
experiments except where noted. To induce expression of CD 14, the putative LPS 
receptor and marker for a more mature (macrophage) phenotype, cells were pretreated for
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24 hours with 0.1 pM vitamin D3. Cells were then labeled with 3H-arachidonic acid 
(specific activity = 200 Ci/mmole) at 0.25 pCi/ml overnight.
Cell Activation. Prior to challenge the cells were washed with warm RPMI, 
resuspended in 25 ml of RPMI, and transferred to 24-well culture plates (1 ml/well). The 
final serum concentration was 2.5%, and final cell densities were between 5 -  8 x 105 
cells/ml. N-acetylsphingosine (C2 ceramide) and dihydroceramide were solubilized in 
ethanol, and LPS was solubilized in 0.1% triethylamine. Controls were included to rule 
out effects of the carriers alone. Endotoxin levels in ceramide and vitamin D3 solutions 
were shown to be below detectable levels by Limulus assay kit (Sigma).
At the end of challenge time periods, samples were removed from the wells, cells 
were removed by centrifugation, and the supernatant was analyzed for released 
eicosanoids. The total tritium-labeled eicosanoids released from cells was determined in 
a Beckman scintillation spectrometer (Model LS6500). Individual eicosanoids (PGE2, 
LTC4, and LTB4) were determined by enzyme immunoassay (EIA) analysis per the 
manufacturer’s instructions (Cayman Chemical).
Desensitization. Cells were treated with 100 ng/ml LPS (R595), 50 (jM C2 
ceramide, or 0.25 U/ml sphingomyelinase (SMase) for 3 hours and then washed and 
resuspended in fresh RPMI with 10% FBS prior to the overnight labeling with 3H- 
arachidonic acid (3H-AA).
Flow Cytometry. After overnight treatment with D3, ceramide (C2), or LPS, 
THP-1 cells were stained with FITC or phycoerythrin (PE) conjugated monoclonal 
antibodies to CD 14 epitopes including anti-CD 14/FITC (M0-P9) from Becton-
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Dickinson and anti-CD 14/PE (MY-4) from Coulter Labs. PE-conjugated monoclonal 
antibodies to constitutively-expressed leukocyte marker, CD45, were used as a positive 
control stain to demonstrate consistent staining o f  samples. The staining period was 30 
min at 4°C. Cells were washed twice with staining buffer (PBS, 0.05% sodium azide, 2% 
FBS) and fixed with 1% buffered paraformaldehyde. PE and FITC conjugated isotype- 
matched negative control antibodies to myeloma proteins were used throughout to 
quantitate nonspecific background binding to target cells. Forward angle (FALS) and 90° 
(orthogonal) light scatter gating eliminated debris and dead cells from the analysis on a 
Coulter elite flow cytometer. Data represents the percentage o f positively stained cells 
for a given antibody, projected beyond the cursors set on negative control histograms to 
separate positively and negatively stained cells. Cursors were set so that 1-2% of all cells 
stained with the negative control, isotype-matched reagents were displayed as being in 
the positive region of the histogram.
RESULTS
Sphingomyelinase and C2 ceramide activated arachidonic acid metabolism in 
THP-1 cells. Arachidonic acid metabolism in THP-1 cells differentiated with 0.1 pM 
vitamin D3, was activated by a wide range of LPS concentrations (0.1 ng/ml -  1000 
ng/ml) in medium containing 2.5% FBS (Fig. 4). Activation was seen with C2 ceramide 
at concentrations as low as 5 pM (Fig. 4) and sphingomyelinase as low as 0.03 units/ml 
(Fig 5).
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Figure 4. LPS and ceramide activate arachidonic acid metabolism in THP- 1  cells.
THP-1 cells were pretreated with vitamin D3 for 24 hr and labeled with 0.5 pC/ml 3H- 
AA overnight. Cells were then washed, resuspended in RPMI with 2.5% FBS, and 
challenged with LPS R595 or C2 ceramide for 3 hr. Cells were removed by 
centrifugation, and 200 pi of supernatant were counted for cpm released. Values are the 
averages of duplicate samples ± range.
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Figure 5. Activation of arachidonic acid metabolism by exogenous bacterial 
sphingomyelinase. Ceils were treated as in Fig. 1 and then challenged with SMase for 3 
hr. Cells were removed by centrifugation, and 200 pi of supernatants were counted for 
cpm released. Values are averages of duplicates ± range, and represent at least two 
experiments.
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Cytotoxicity, as measured by trypan blue uptake, was observed at concentrations o f LPS 
above 1000 ng/ml, C2 ceramide above 100 pM, and sphingomyelinase above 1 unit/ml. 
Dihydroceramide, due to poor uptake by cells, was used as a negative control, and 
elicited little or no response (data not shown).
The response of THP-1 cells to simultaneous challenge with both LPS and ceramide 
depended on concentrations of these agents. At lower concentrations o f  both LPS and 
ceramide, release was slightly higher than with either agent alone (Table 1), but at higher 
concentrations of LPS, the addition of ceramide had little effect.
TABLE I
Concomitant challenge of THP-1 cells with LPS and ceramide*
LPS Concentration (ng/ml)
0 .1 1
Ceramide
0 pM 0 405(16)b 441(5)
40 pM 208(9) 605(11) 691(33)
60 pM 359(5) 852(35) 840(5)
10
619(6)
764(64)
987(13)
100
1436(88)
1503(48)
1446(21)
1000
1844(61)
1789(97)
1664(15)
a) THP-1 cells were treated and labeled as in Fig. 1 and challenged for 2 hr with LPS 
(ng/ml) and C2 ceramide (pM) alone and together. 200 pi of post-challenge supernatant 
were counted for label released from the cells.
b) Values show cpm released from 1.5 x 10s cells above control values, and are averages 
o f duplicate samples + range.
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Prostaglandin E2/Leukotriene C4  molar ratios were higher from LPS-treated 
cells than from ceramide-treated cells. Untreated (control) cells released 40 ±9 pg/ml 
o f PGE2 and 23 ±11 pg/ml o f LTC4  during the 3 hour incubation period. The ratio of 
PGE2/LTC4 in the lipid released from LPS treated cells was about 10 times the value for 
untreated cells. In contrast the molar ratio of PGE2/LTC4  in the lipid released from 
ceramide treated cells remained constant (Fig. 6a). This difference resulted from a higher 
production of prostaglandin from LPS treated cells (Fig. 6b). Interestingly, the 
PGE2/LTC4 ratio increased as the concentration of LPS increased, but remained fairly 
constant at all concentrations o f ceramide even though there were increases in both PGE2 
and LTC4  to approximately 100 pg/ml. This suggests that whereas LPS activated cyclo- 
oxygenase activity above constitutive levels, ceramide increased PG and LT release only 
through increased availability o f arachidonic acid via PLA2 activation, and not through 
specific induction of cyclo-oxygenase or lipoxygenase pathways. The amount of PGE2 
from cells treated with SMase was very similar to that o f LPS-treated cells, increasing to 
give a PGE2LTC4  ratio that was a log higher at maximal SMase concentration than 
constitutive levels from untreated cells (Fig. 6c). LTB4 did not significantly increase 
following challenge with any o f the activators (data not shown).
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Figure 6 A & B. PGE2/LTC4 molar ratios released from THP-1 cells. Supernatant 
samples from experiments performed as in Fig. 1 and 2 were assayed for PGE2 and LTC4 
by EIA, following procedure provided with the assay kits. A) Ratios in pg/ml were 
converted to molar ratios and plotted for cells treated with LPS (top axis) and C2 
ceramide (bottom axis). B) Quantities of PGE2 and LTC4 from A expressed as pg/ml. 
Values are averages of duplicate samples.
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Figure 6. (continued) C) PGE2 and LTC4 in pg/ml from cells treated with SMase. 
Values are the averages of duplicates.
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Desensitization of THP-1 cells. Pre-exposure to LPS induces a tolerant state 
during which subsequent challenge with LPS fails to activate several pathways 
(27,41,96). In our studies, an initial 2-3 hour treatment of THP-1 cells (or murine 
peritoneal macrophages) with 100 ng/ml LPS desensitized them to subsequent challenge 
with a wide range of LPS concentrations so that eicosanoid release remained near control 
levels even 20 hours after pretreatment. To determine whether ceamide had the same 
effect, we treated THP-1 cells with either LPS (100 ng/ml), ceramide (50 |iM), or SMase 
(0.25 U/ml) for 3 hours, then labeled the cells overnight with 3H-AA. Cells were then 
challenged with LPS, ceramide, or SMase (Fig. 7). In terms of 3H-AA release, LPS 
desensitized cells to challenge with LPS (Fig. 7A), and partially to challenge with SMase 
(Fig. 7C). Pretreatment with SMase desensitized cells to challenge with SMase (Fig. 7C) 
and partially to challenge with LPS (Fig. 7A), but primed them for challenge with C2 
ceramide (Fig. 7B). Pretreatment with C2 had very little effect on LPS or C2 challenge 
(Figs. 7A&B), but primed the cells for SMase challenge (Fig. 7C).
In order to determine whether pretreatment affected the PGE2/LTC4 ratio in the lipid 
released from cells after subsequent challenge, the amounts of PGE2 and LTC4 were 
determined for supernatants o f cells pretreated with either medium alone (control), LPS 
(100 ng/ml), C2 ceramide (40 |tM), or Smase (0.25 U/ml), then challenged with 100 
ng/ml LPS. Pretreatment with LPS almost completely blocked the increase in PGE2 
production following subsequent challenge with LPS. Interestingly, both SMase and C2 
ceramide also reduced the amount o f PGE2 produced after LPS challenge, but only to 
about half the amount produced from non-pretreated cells (Fig. 8).
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Figure 7. Pre-exposure to LPS, but not ceramide, desensitized THP-1 cells to 
subsequent challenge. THP-1 cells were pretreated with D3 as in Fig. 1, then treated 
with medium alone (control) (•), 100 ng/ml LPS (o), 0.25 U/ml Smase (A), or 50 piM C2 
ceramide (a) for 3 hr. Cells were resuspended in fresh medium and labeled overnight 
with 3H-AA. They were then washed and challenged with LPS (A), ceramide (B), or 
SMase (C) for 3 hr. Values show relative response of cells after various treatments as the 
amount o f label released per 1.5x10s cells divided by the amount of label released from 
unchallenged control for each sample, and are averages of duplicates.
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Figure 8. Pre-exposure to LPS, C2 ceramide, or SMase reduced the PGE2/LTC4 
m olar ratios released from THP-1 cells challenged with LPS. THP-1 cells were 
pretreated as in Fig. 4, and labeled overnight. The cells were then washed and challenged 
in RPMI with LPS at concentrations shown. Supernatants were assayed for PGE2 and 
LTC4  by EIA, following the procedure provided with the assay kits. Ratios in pg/ml 
from a standardized curve for averaged duplicate samples were converted to molar ratios.
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DISCUSSION
Recent studies have shown that TNFa, ILip, and LPS share many biological effects 
and activate common kinases and transcription factors such as CAPK, MAP kinase, and 
NF-kB (51,104). However, LPS does not activate sphingomyelinase or cause 
accumulation of ceramide (52). Based on these observations, researchers (52,107) have 
suggested that LPS may simply mimic ceramide itself. Other observations which appear 
to be consistent with this hypothesis include the inability of cells from LPS- 
hyporesponsive C3H-HeJ mice to respond to ceramide (8), the structural similarity 
between ceramide and the reducing glucosamine of lipid A (52), and the activation of a 
subset of LPS-inducible genes by the sphingomyelinase pathway (7).
LPS, C2 ceramide, and SMase all activated arachidonic acid metabolism as measured 
by the release of 3H-AA. At low concentrations o f both LPS and ceramide, simultaneous 
challenge with both agents enhanced the response of THP-1 cells and resulted in an 
additive to slightly synergistic effect. At higher concentrations of LPS, however, this 
effect was lost, and the amount o f 3H-AA released was reduced below the levels seen 
with LPS alone (Table 1). If LPS and ceramide were using separate pathways for 
arachidonic acid metabolism, we expected to see an additive effect at all concentrations 
since the amounts released through each pathway would be independent o f the other. 
However, loss of this effect at higher concentrations may provide evidence of a shared 
pathway or signaling component that can be saturated.
These results, simply measuring the release of labeled arachidonic acid metabolites, 
are consistent with the mimicry model. However, it is important to look at specific
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eicosanoids released because studies in our lab have shown that free arachidonic acid 
accounts for the major portion (approximately 65%) o f the label released from treated 
cells (R. Wang thesis, UM, 1997), so that variations in the relative amounts o f the other 
metabolites would not be apparent. We were able to show that although both LPS and 
ceramide activated 3H-AA release, they induced very different ratios of PGE2 to LTC4 .
As shown previously (33,76,105), LPS activated the synthesis o f prostaglandins, but not 
leukotrienes, in a concentration-dependent manner. Treatment with SMase also 
stimulated PG synthesis and high PGE2/LTC4 ratios. However, ceramide-treated cells 
showed slight increases in both PGE2 and LTC4, maintaining a stable ratio near 
constitutive levels. This may simply be due to increased PLA2 activity and available 
arachidonic acid, although most of the AA was not metabolized further. These results 
suggest that for induction of arachidonic acid metabolism, exogenous SMase more 
closely mimics LPS action than C2 ceramide. The reason for this is unclear. However, 
exogenous SMase acts at the outer leaflet of the membrane and may release ceramide 
from a different pool of sphingomyelin so that it has different signaling properties than 
C2 ceramide or ceramide released by endogenous SMase (109).
For several effects of ceramide (as second messenger for TNFa and IL-1 receptors) 
and LPS, a common target appears to be ceramide-activated protein kinase (CAPK) 
which leads to activation of MAP kinases and the translocation of activated NF-kB (52). 
CAPK may also be involved in the release of eicosanoids. In fact, Schutze (80) has 
shown that the TNF receptor has two catalytic domains. One domain activates an acid 
sphingomyelinase and leads to NF-kB activation, and another domain activates a neutral
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sphingomyelinase which leads to arachidonic acid release by PLA2 via CAPK. Jayadev 
(51) showed that LPS activated CAPK in HL-60 cells at low concentrations and that it 
was mediated by CD 14. Higher concentrations o f LPS are able to activate some 
signaling pathways independent of CD 14, which suggests that, like ceramide, there are at 
least two mechanisms by which LPS activates signal transduction. It seems possible, 
therefore, that LPS may mimic ceramide inasmuch as it can activate a common target, 
CAPK, but that some of its activities occur without this shared mediator (Fig. 9).
Additional support for a model in which LPS and ceramide use separate pathways 
for arachidonic acid metabolism comes from our desensitization studies. Pretreatment of 
THP-1 cells with LPS desensitizes cells to subsequent challenge with LPS even up to 
1000 ng/ml. However, pre-treatment with LPS did not affect the release of label after 
challenge with C2 ceramide. Pretreatment with C2 ceramide had little effect on LPS 
challenge, but primed them for release following SMase challenge. Like desensitization, 
priming o f immune cells for subsequent challenges is an important part of the regulation 
of the immune response (26,74), and results in a much higher release of mediators than 
that seen without the pretreatment. Because the response of THP-1 cells to LPS differs 
so dramatically from their response to ceramide treatment, our results suggest that LPS 
and ceramide do not share a single regulatory pathway. It is possible that LPS may use 
another membrane target containing a regulatory mechanism that is independent of the 
CAPK pathway. It is also possible that these results are due instead to an autocrine effect 
by the high levels of prostaglandins released by LPS-treated cells. PGE2 has been 
implicated in the autocrine down-regulation of nitric oxide synthase and tumoricidal
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Figure 9. A hypothetical scheme of signaling pathways for arachidonic acid 
metabolism activated by LPS or ceramide, and the putative shared pathway of 
ceramide mimicry by LPS. Compiled from various works, as sited in the text.
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activity in mouse macrophages (76), and of TNF in a human monocytic cell line (41). If 
a high PGE2/LTC4 ratio is required for desensitization, it may explain why LPS, but not 
ceramide, is able to desensitize cells to subsequent challenge. It is interesting that 
SMase, which also caused the release of high PG/LT ratios, was also able to partially 
desensitize cells to subsequent challenge.
Our data strongly suggest that there are significant differences in the signaling 
pathways for LPS and ceramide in terms of specific eicosanoids released and in terms of 
regulation by desensitization. Because of the critical role prostaglandins and leukotrienes 
play in modulating the immune response, these differences are particularly important. 
Perhaps even more interesting is our evidence that C2 ceramide and exogenous 
sphingomyelinase had very different effects. Continuing studies are needed of the 
specific pools o f sphingomyelin from which ceramide is released endogenously by 
various agents. This will then allow us to explore the possibility of separate pools of 
arachidonic acid subsequently released as the substrate for cyclo-oxygenase, located in 
the endoplasmic reticulum, and soluble 5-lipoxygenase. There is evidence that this kind 
o f compartmentalization allows for the production of prostaglandins, but not leukotrienes, 
by LPS (50).
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CHAPTERS
MONOCLONAL ANTIBODIES TO CD45 MODIFY LPS-INDUCED 
ARACHIDONIC ACID METABOLISM IN MACROPHAGES
Introduction
Considerable evidence has accumulated that macrophage activation by LPS occurs via 
a receptor complex consisting of a receptor (CD 14) and associated tyrosine kinases o f the 
src family (32,43,60,98). Signaling through CD 14 has several similarities to the signaling 
through the T cell and B cell receptors. These include 1) a requirement for a means to 
transmit the message into the cell due to the lack of a cytosolic tail on the receptor, 2) 
activation of protein tyrosine kinases of the src family, and 3) proliferation o f multiple 
signals. The initial dramatic increase in tyrosine phosphorylation is transient (99), which 
suggests that a regulatory mechanism removes the phosphate groups. It seems likely that 
this would be a protein tyrosine phosphatase (PTPase) activity.
CD45, the Leukocyte Common Antigen, is a transmembrane protein tyrosine 
phosphatase (PTPase) that plays a major role in signal transduction in T cells, B cells, 
natural killer cells, and neutrophils (44,58,61,62,87). It is the most abundant and well 
characterized of the family of transmembrane protein tyrosine phosphatases in 
hematopoietic cells (2,58). The molecule (Fig. 1) consists of three domains: a large, 
extensively-glycosylated extracellular N-terminal domain, a single transmembrane domain, 
and a cytosolic C-terminal domain that contains two protein tyrosine phosphatase 
activities (86,89). One of these activities appears to be an autoregulatory protein tyrosine
82
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phosphatase (102). Alternative splicing of three variable exons encoding portions of the 
extracellular domain leads to expression of several isoforms o f CD45. These range in 
molecular weight from 180 -  240 kD, and their expression is tightly regulated during 
development and activation of lymphocytes (93).
390*550 aa 
Extracellular Domain
Cell Membrane
700 aa
Cytoplasmic Domain
30 -1 8 0  aa N-Terminal Domain 
'(O-linked glycosylation, isoform 
specific)
360 aa Cysteine-Rich Domain 
(N-linked glycosylation)
-  22 aa Transmembrane domain
_ 240 aa Catalytic Domain 1 
(PTPase)
-  240 aa Catalytic Domain 2 
(PTPase)
COOH
Figure 1. CD45 protein tyrosine phosphatase (Leukocyte Common Antigen)
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Although found on monocytes and macrophages (39,61,64,77), CD4S has 
primarily been studied in lymphocytes. Such studies have demonstrated that CD4S is part 
of the receptor complexes on T and B cells, in which its major substrates for 
dephosphorylation appear to be protein tyrosine kinases (PTK) (2,15,87). This suggests 
that CD45 has a regulatory role in proximal signal transduction by modulating the 
phosphorylation - dephosphorylation equilibrium, thereby coupling specific surface 
receptors to downstream tyrosine kinase-dependent signaling. CD45 is involved in both 
positive and negative regulation depending on whether the particular kinase substrate has 
phosphorylated tyrosines at inhibitory sites or activation sites (93).
Studies regarding the roles of CD4S in monocytes and macrophages are much 
more limited. CD4S expression has recently been shown to be up-regulated on activated 
epithelium-lining macrophages (94), and C5a-activated monocytes (23). There is some 
evidence for CD45 involvement in monocyte adherence (64), in synergizing with LPS in 
triggering M-CSF production (39) and respiratory burst in monocytes (61), and in 
regulation of Fey receptor-induced calcium mobilization (53,77). Thus, it is clear that 
CD45 may be involved in several aspects o f macrophage activation. However, very little 
is known about the role of CD45 in the activation o f macrophages by LPS. Since 
activation by LPS via CD 14 results in tyrosine phosphorylation (60), this pathway is most 
likely regulated by a protein tyrosine phosphatase. Although tyrosine phosphorylation has 
been associated with eicosanoid biosynthesis in macrophages (33), there have been no 
studies linking CD45 to the regulation o f arachidonic acid (AA) metabolism, another 
important result of macrophage activation. B cells have been shown to be able to respond
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to LPS independent of CD45 (55), but it is possible that this is via a CD 14-independent 
pathway such as polyclonal linkage of surface IgM.
The major objective o f this study was to determine whether or not the CD45 
protein tyrosine phosphatase plays a role in the activation and desensitization of 
arachidonic acid metabolism by LPS in THP-1 cells. The hypothesis was based on the role 
o f CD45 in T cells and the apparent similarity between that signaling system and the one 
used by LPS via CD 14, including the evidence of a receptor complex, activation of 
tyrosine kinases, and the transient nature of the tyrosine phosphorylation induced by ligand 
binding. Anti-CD45 monoclonal antibodies (mAb) to CD45 were used to explore 
expression of CD45 on THP-1 cells, to measure their effect on activation and 
desensitization of AA metabolism by binding or cross-linking surface CD45, and to 
correlate these effects with signaling through the CD 14 pathway.
MATERIALS AND METHODS 
Materials: THP-1 cells were purchased from American Type Culture Collection 
(Rockville MD). Balb/C and Swiss Webster mice were obtained from Jackson 
Laboratories. Cellgro RPMI 1640 was from Mediatech (Herndon VA), and defined fetal 
bovine serum (FBS) was purchased from HyClone (Logan UT). Purified LPS R595 from 
S. minnesota, monophosphoryl lipid A (MLA), and diphosphoryl lipid A (DPL) were 
provided by Ribi Immunochem Research (Hamilton MT). Tritiated arachidonic acid was 
purchased from American Radiolabeled Chemical Co. (St. Louis MO). Vitamin D3 (la , 
25-dihydroxyvitamin D) was purchased from Calbiochem (LaJolla CA). Anti-CD45, anti- 
CD45RA, anti-CD45RO, and M 0-P9 anti-CD 14/FITC monoclonal antibodies and
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isotype-matched negative controls were from Becton-Dickinson Immunocytometry 
Systems. Anti-mouse anti-CD45 monoclonal antibodies (HI-30) were from Pharmingen 
(San Diego CA). Enzyme Immunoassay Kits were obtained from Cayman Chemical Co. 
(Ann Arbor MI). Anti-CD45 (BRAS 5 biotin-conjugated), anti-CD 14 (UCHM-1 biotin 
conjugated), isotype matched controls, anti-phosphotyrosine (biotin-conjugated), avidin, 
and all other chemicals were purchased from Sigma Chemical Co. (St. Louis MO).
Cell Culture. Murine peritoneal macrophages were harvested from mice by 
peritoneal lavage using 10 ml RPMI with 10 pg/ml gentimicai injected into the peritoneal 
cavity. Cells were plated to 24-well plates and, after a two hour adherence period, non­
adherent cells were washed off, and fresh medium was added. THP-1 cells were grown in 
RPMI supplemented with 10% FBS, 100 U penicillin, 0.1 mg/ml streptomycin, and 2 mM 
L-glutamine, and maintained between 2 -  6 x 10s cells/ml at 37° C with 5% CO2 . Viability 
remained above 97% (by trypan blue exclusion) throughout the experiments except where 
noted. THP-1 cells were pretreated for 24 hours with 0.1 pM vitamin D3 to induce 
expression of CD 14, the putative LPS receptor and marker for a more mature 
(macrophage) phenotype. They were then labeled with 3H-arachidonic acid at 0.25 |iCi/ml 
overnight.
Cell Activation. Prior to challenge the cells were washed with warm RPMI, 
resuspended in 25 ml of RPMI, and transferred to 24 well culture plates (1 ml/well). The 
final heat-inactivated serum concentration was 2.5 -  5%, and final cell densities were 
between 5 -  8 x 10s cells/ml. LPS was solubilized in 0.1% triethylamine in a 100 mg/ml 
stock solution. Monoclonal antibodies were titered for use at approximately 2 (ig/ml for
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
87
106 cells, and diluted in RPMI. Controls were included to rule out effects o f the carriers 
alone. Isotype-matched anti-myeloma protein mAb were used to rule out effects of 
binding by FcR on the macrophages. Endotoxin levels of vitamin D3 and media solutions 
were shown to be below detectable levels by Limulus assay.
At the end of challenge time periods, samples were removed from the wells, cells 
were pelleted by centrifugation, and 200 jjJ of the supernatant were counted in a 
Beckman scintillation counter to determine the amount of radiolabeled arachidonic acid 
metabolites released. Supernatants were also assayed for specific eicosanoids 
(prostaglandin E2, leukotriene B4, and leukotriene Gt) using EIA kits, following 
manufacturer’s instructions (Cayman).
Desensitization. Cells were treated with 100 ng/ml LPS (R595), with or without 
anti-CD45, for 3 hours and then washed and resuspended in fresh RPMI with 10% heat- 
inactivated FBS prior to the overnight labeling with 3H-arachidonic acid (3H-AA).
Cross-linking of surface receptors. Cross-linking of CD4S and CD 14 was 
accomplished in two ways. First, cells were treated with Anti-CD45 2D1 for 10 min at 1 
|ig/ml, then washed and plated to wells in 24-well plates at 5x10s cell/ml. Anti-mouse IgG 
was added at 1 |ig/ml to cross link the bound mAb prior to challenge. Second, cells were 
treated as above with biotinylated anti-CD45. Cells were then washed to remove free 
mAb. Avidin was then added at 30 pl/ml prior to challenge.
Flow cytometry. After overnight treatment with LPS R595, MPL, or C2 
ceramide, D3 pretreated THP-1 cells were stained with FITC or phycoerythrin (PE) 
conjugated monoclonal antibodies to CD45, CD45RA, and CD45RO from Becton-
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Dickinson. The staining period was 30 min. at 4° C. Cells were washed twice with 
staining buffer (PBS, 0.05% sodium azide, 2% FBS) and fixed with 1% buffered 
paraformaldehyde. PE and FITC conjugated isotype-matched negative control myeloma 
proteins were used throughout to quantitate nonspecific background binding to target 
cells. Forward angle (FALS) and 90° (orthogonal) light scatter gating eliminated debris 
and dead cells from the analysis on a Coulter Elite flow cytometer. Data represent the 
percentage o f positively stained cells for a given antibody, projected beyond the cursors 
set on negative control histograms to separate positively and negatively stained cells. 
Cursors were set so that 1-2% of all cells stained with the negative control, isotype- 
matched reagents were displayed as being in the positive region of the histogram.
SDS-PAGE and Western Blotting. D3-pretreated THP-1 cells (1 x 107) were 
lysed in 1 ml lysis buffer for 1 hr at 4° C. (Lysis buffer = 1% Triton X100, 20mM Tris 
HC1 (pH 7.4), 137 mM NaCl, 2mM EDTA, ImM phenylmethylsulfonylfluoride (PMSF), 1 
pg/ml each of pepstatin, aprotinin and leupeptin, 1 mM sodium orthovanadate (NaVO-t), 
and 100 pM phenylarsine oxide (PhAsO).) The lysate was pelleted at 10,000 g for 30 
min, and supernatants were transferred to fresh tubes. For immunoprecipitation, 20 pi of 
anti-CD45 was added and incubated for 2 hours at 4° C. 50 jj.1 of protein-G sepharose 
was then added and incubated at 4° overnight on an inverter shaker. Precipitate was 
washed twice in lysis buffer, and once in wash buffer (50 mM Tris HCI 7.4, 200 pM 
NaVC>4, 100 PhAsO). Samples were boiled for 5 min prior to loading onto 7.5% 
SDS-PAGE gels. Gels were run in a BioRad Minigel apparatus for 40 -  60 min, then 
blotted onto PDVF membranes. Blots were stained with primary antibodies or with
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biotinylated Abs for 2 hours at room temperature in blocking buffer, then washed for 30 
min. If  needed, biotinylated 2° antibody was used to stain the primary Ab, and the 
membrane was washed again. Blots were stained for 1 hour at room temperature in 
blocking buffer with streptavidin:horseradish peroxidase, then washed 15 min with 60° 
wash buffer, and subsequent washes at 37° for 15 min and 5 min. Blots were developed 
and films exposed using enhanced chemiluminescence (ECL) kits from Amersham.
RESULTS
TUP-1 cells express CD45 constitutively. Figure 2 shows flow cytometry 
histograms from cells stained with three different monoclonal antibodies (mAb) specific 
for three of the CD45 isoforms commonly expressed on leukocytes. Each histogram has a 
peak representing the percent of cells in the gated population that stained positively with 
the indicated antibody. The position of the peak on the X axis shows mean channel 
fluorescence, a measure of how brightly the cells are stained. The first two histograms 
show staining with negative control, (IgGi/IgGa) conjugates, phycoerythrin (A) and FITC 
(B). The cursors are set on these controls so that only a small percentage (0 .1 -1 .6% ) of 
the cells staining with the negative controls are counted as positive. Histogram C shows 
that 24.5% of the gated cells stained with anti-CD45RO/PE with a mean fluorescence o f
3.52. Generally, CD45RO is the isoform expressed on activated T cells, and CD45RA is 
more often expressed on quiescent cells. Histogram D shows 63.1% of the cells stained 
positive with anti-CD45RA/FITC with a mean fluorescence of 0.628. This means that 
although more cells expressed CD45RA, there were significantly fewer molecules
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expressed/cell than CD45RO. Histogram £  shows 95.7% of the cells stained positive for 
anti-CD45, a mAb that recognizes all known isoforms of CD45, at a mean fluorescence o f
9.52.
This pattern did not change significantly following treatment with LPS, MPL, or 
ceramide (Table 1), suggesting that activation of macrophages by these agents does not 
alter expression of CD45 isoforms. There was a 50% reduction in % positive cells stained 
for isoforms RO and RA after treatment with C2 ceramide. Little is known about the 
regulation o f CD45 isoforms on macrophages, and I did not explore this using THP-1 cells 
since it would have required comparing expression on these cells with several other cell 
systems. The alteration in expression following C2 treatment was intriguing, however, 
and would make another interesting study.
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
91
6: FS PEAKvsSSc LOG 6: FS PEAKvsSSc LOG
c
%U _|yv _______________ c3  - O 4---------------------------------------------------------
1 M
6: FS PEAKvsSSc LOG
100 1000
c3ou  j
"i— r r n nn r '~ rn iinii
- 1 1 f c
G: FS PEAKvsSSc LOG
l 11 min i i mini 
100 1000
3Ou
01 1
. 1  1 
G: FS PEAKvsSSc LOG
10
FITC
100 1000
i 11nun 
. 1  1
ii i n inni i 11 mm 
10 100 1000 
FITC
STATISTICS
SINGLE PARAMETER STATISTICS
* e e * e .Peak e * e e • e
10 Pent Are* P o s it io n  1Height Mean SO FullCV Hal-FCU Min Max
A 7 .2  35G 1 .7 12 2 .4 2 1 .1 4 4 7 .2 1 .4 3 1 .6 1024
B 1 .9  93 0 .1 4 3 0.311 0 .2 8 3 9 1 .2 0 .6 6 8 0 .1 2 1024
C 2 4 .5  1225 1 .7 19 3 .5 2 2 .3 7 6 7 .3 0 .9 3 8 1 .6 1024
0 4 3 .1  3154 0 .8 1 18 0 .6 2 8 0 .6 9 9 111 .3 0 .4 9 4 0 .1 2 1024
E 9 5 .7  4783 5 .4 30 9 .5 2 9 .1 8 9 6 .4 1 2 .3 1 .6 1024
A Low Channel * 1 .6 , High Channel -  1024 C
B Low Channel * 0 .1 2 , High Channel = 1024 B
C Low Channel = 1 .6 , High Channel -  1024 C
0 Low Channel * 0 .1 2 , High Channel « 1024 B
E Low Channel * 1 .6 , High Channel ■ 1024 C
Figure 2. CD45 expression on THP-1 cells. D3-pretreated THP-1 cells were stained 
for flow cytometry as described in Materials and Methods. A)IgGi/IgG2a isotype matched 
control conjugated with phycoerythrin; B) IgGi/lgCha isotype control conjugated with 
FITC; C) Anti-CD45RO/PE; D) anti-CD45RA/FITC; E) anti-CD45/PE.
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TABLE 1
Surface expression of CD45 isoforms on vitamin D3-pretreated THP-1 cells 
following treatment with medium, LPS, C2 ceramide, or MPL, as measured by flow 
cytometry.'
a) THP-1 cells were treated for 18 hr with medium only (control), 100 ng/ml LPS R595, 
1000 ng/ml MPL, or 40 pM C2 ceramide. Cells were then stained and analyzed by flow 
cytometry as described in Materials and Methods.
b) Percent of gated (90° vs FALS) cells staining positive
c) Mean channel fluorescence -  4 decade logarithmic range
When whole cell lysates were separated by PAGE and Western blotted, anti-CD45 
clone BRA55 (Sigma) stained a set of three bands at 240, 200, and 180 kD (Fig. 3a). This 
suggests that the full range of isoforms sizes are expressed on THP-1 cells, all of which 
contain the epitope bound by BRA55. Anti-CD45 2D1 (Becton-Dickinson) stained a 
single band at 220 kD (Fig. 3b).
TREATMENT: Control LPS MPL Ceramide
aCD45RA 61.4
0.6
53.9
0.557
35.7
0.428
a CD45RO 24.5
3.52
27.4
3.43
25.2
3.64
12.5
3.3
aCD45 (pan) 95.7
9.52
97.1
14.2
97.8
11.2
97.7
11.3
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Figure 3. Western blot of CD45 on THP-1 cells. Whole cell lysates of D3-pretreated 
THP-1 cells in sample buffer were loaded onto 7.5% SDS-PAGE gels and run in a 
min-gel apparatus for 40 min. Proteins were then blotted onto PDVF membranes. 
Blots were stained with either biotinylated anti-CD45 BR.A55 (a), or anti-CD45 2D1 
followed by 2° biotinylated anti-mouse anti-IgG (b), and then streptavidin:HP. Blots 
were developed and films exposed using ECL.
Anti-CD45 mAb increased the release of labeled arachidonic acid metabolites 
and TNF from LPS-challenged cells. Addition of anti-CD45 2D1 just prior to 
challenge with LPS increased the release of Aa slightly (Fig. 4a), but when added 18 hr 
prior to challenge there was a 2-fold increase over the amount released from cells
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challenged only with LPS (Fig. 4b).
Similar results were seen when mouse peritoneal cells (PECs) were treated with 
anti-mouse aCD45 18 hours prior to challenge (Fig. 5). Like the increase seen with THP- 
1 cells, aCD45 resulted in at least a doubling o f the amount o f 3H-AA released.
Macrophages express Fc receptors (FcR) for binding particles opsonized with 
antibodies. Binding of FcR can lead to activation of several pathways (21,77). To 
determine whether FcR activation was a factor in the increased arachidonic acid release, 
THP-1 cells were treated with isotype matched control antibodies for 2 hours. Figure 6a 
shows that although LPS and anti-CD 14 UCHM-1 activated AA release, anti-CD45 2D1 
had only a slight effect by itself. IgGi (isotype control for 2D1) and IgG^ (isotype control 
for UCHM-1) had no effect. Fig. 6b shows that the isotype matched negative control 
IgGi did not have any effect on LPS challenge.
Anti-CD4S 2D1 affected a signaling pathway activated by LPS other than 
arachidonic acid metabolism, that leading to TNFa production. It had no effect alone on 
TNF production, but synergized with LPS to release 33-42% more TNF from cells treated 
with 1-10 ng/ml of LPS, respectively (Fig. 7).
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Figure 4. Anti-CD45 mAb increased 3H-AA release from LPS-challenged THP-1 
cells. D3-pretreated THP-1 cells were labeled overnight with 0.5 |j.C/mI 3H-AA, then 
washed and resuspended in RPMI for plating in 24-well plates at 1.5xl06 cells/well. 
aCD45 2D1 was added either immediately prior to challenge (a), or 18 hours prior to 
challenge (b). The cells were challenged with LPS R595 at concentrations shown for 3 hr. 
Supernatants were centrifuged to remove cells, and 200 jJ  of supernatants were counted 
for cpm released. Values represent cpm released from 3x10s cells above control values 
for cells challenged with medium alone, and are averages o f duplicates ± range.
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Figure 5. Anti-CD45 increased 3H-AA release from LPS-challenged mouse 
peritoneal exudate cells (PECs). PECs were harvested from 6-week old Balb/C mice 
and plated in 24-well plates. After a 2 hr adherence period, non-adherent cells were 
removed by washing, and adherent cells were labeled overnight as before, one plate 
containing anti-mouse aCD45, 1 pg/ml) and one plate with no mAb. Wells were washed 
and cells were challenged with LPS R595 for 2 hr. Values represent cpm released above 
control values for unchallenged cells, and are averages of duplicates ± range.
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Figure 6 . Isotype-matched control antibodies had no effect on AA release. D3-
pretreated THP-1 cells were labeled overnight as before, then washed and plated at 5x10 
cells/well. LPS (1 pg/ml) or 1 pg/ml of the various antibodies were added to wells. The 
mAbs used were aCD45 2D1 (Becton-Dickinson, IgGi), IgGi isotype control (Becton- 
Dickinson), aCD 14 UCHM-1 (Sigma, IgG^), and IgG^ isotype control (Sigma). Cells 
were challenged for 2 hr, then 200 jil of supernatants were counted for cpm released. 
Values are averages of duplicates ± range.
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Figure 7. Anti-CD45 increased release of TNFa from THP-1 cells challenged with 
LPS. Vitamin D3-pretreated THP-1 cells were challenged for 20 hr with LPS R595 at 
concentrations shown, with or without 1 (ig/ml aCD45 2D1. Supernatants were assayed 
for TNFa released by ELISA according to manufacturer’s instructions. TNFa in pg/ml 
was calculated from a standard curve.
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Cross-linking of CD45 inhibited LPS-induced activation of AA release.
CD45 was cross-linked on THP-1 cells using two methods. Anti-CD45 was allowed to 
bind to cells for 10 minutes prior to the addition of either avidin (to cross-link biotinylated 
anti-CD45), or anti-mouse IgG (to cross-link the Fc domains o f the bound anti-CD45). 
Figure 8 shows that both methods reduced AA release significantly from that released 
from LPS-challenged cells. IgGi isotype control and the anti-mouse IgG mAb had no 
effect.
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Figure 8 . Cross-linking CD45. D3-pretreated THP-1 cells were labeled overnight with 
3H -A A , then divided into flasks containing either medium alone of 1 pg/ml of anti-CD45 
BRA55. After 10 min to allow binding, cells were washed and resuspended in fresh 
medium, and plated at 5x10s cells/well. Either anti-mouse algG  (1 ng/ml) or 20 pi avidin 
were added to cross-link via Fc domains or biotinylated aCD45, respectively. Cells were 
then challenged with LPS R595 for 2 hr. 200 pi of cell-free supernatants were counted 
for cpm released. Values represent relative response, calculated by dividing cpm released 
from challenged cells by the cpm released from unchallenged cells, and are averages of 
duplicates.
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Desensitization and anti-CD45. As shown in previous chapters, LPS 
pretreatment dramatically reduces eicosanoid release following subsequent challenge. 
Figure 9 shows that anti-CD45 added during the desensitization period (2-3 hours) did not 
affect the ability of LPS to desensitize the cells. However, addition of anti-CD45 during 
that period without LPS resulted in increased release after subsequent challenge. 
Therefore, treatment of these cells with anti-CD45 18-20 hours prior to challenge 
increased release of AA even if the unbound antibodies are washed away after 2 hours, 
although to a lesser extent than if the mAb were left in overnight.
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Figure 9. Pretreatment with aCD45 had no effect on desensitization by LPS. D3-
pretreated THP-1 cells were treated with medium alone, 100 ng/ml LPS R595, 1 pg/ml 
aCD45 2D1, or LPS and aCD45 together for 3 hr. The cells were then washed and 
labeled overnight as before. They were washed and plated at lx l0 6/well, and challenged 
with LPS at 1 pg/ml for 2 hr. 200 1̂ of cell-free supernatants were counted for cpm 
released above controls, and values are averages of duplicates.
All challenged with 1000 ng/ml LPS R595
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
101
Production of prostaglandin E2 . One of the important eicosanoids released from 
LPS-activated macrophages is PGE2 (see Chapter 4). Figure 10 shows that anti-CD45 
increased production of PGE2 from LPS-challenged cells. There was no production of 
LTC4 or LTB4 with either LPS, LPS and anti-CD45, or anti-CD45 alone (data not 
shown). This suggests that, in terms of prostaglandin and leukotriene production, anti- 
CD45 simply increased the signal generated by LPS, but did not change which signaling 
pathways were activated. This is further evidence that the effect seen with anti-CD45 is 
not due to FcR binding, since activation of signaling by FcRy has been shown to cause the 
production of LTB4 from both monocytes and PMNs (49,83).
0.1 1.0 10 100 1000 
LPS CONCENTRATION (ng/ml)
Figure 10. aCD45 increased PGE2 released from LPS-challenged cells. Samples 
from Fig. 3 were assayed for PGE2 using EIA, following manufacturer’s instructions. 
PGE2 in pg/ml was calculated from a standard curve. Values are pg/ml released above 
control, and are averages of duplicates.
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Correlation of the effects of anti-CD45 with signaling through the CD14 
signaling pathway. Because LPS activates tyrosine phosphorylation via CD 14 (33), this 
pathway is likely to have an associated protein tyrosine phosphatase. This series of 
experiments was done under conditions that emphasized signaling through CD 14. CD 14 
specifically binds complexes of LPS and its serum binding protein, LBP. Therefore, THP- 
1 cells were challenged in medium without serum to determine the effect of anti-CD45 in 
the absence of LBP. Rather than the dramatic increase seen in medium containing 5% 
serum (Fig. 4), a slight reduction in release was seen with anti-CD45 in the absence of 
serum (Fig. 11).
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Figure II. Lack of serum in the challenge prevented the increase in AA release by 
aCD45. D3-pretreated THP-1 cells were labeled and challenged as in Fig. 3 except that 
no serum was added to challenge medium. Values represent cpm released in 200 pj of 
cell-free supernatants, and are averages of duplicates ± range.
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Pretreatment of THP-1 cells with vitamin D3 increases CD 14 expression 50-80% 
(Chapter 2, Table 1). Therefore, effects o f aCD45 were compared on cells treated with 
D3 to cells that were not pretreated with D3. Without D3 pretreatment, aCD45 had very 
little effect except at the highest LPS concentration (100 ng/ml) (Fig. 12). The effect was 
seen with cells treated with D3 even at the lowest concentration of LPS tested (0.1 ng/ml).
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Figure 12. Pretreatment with vitamin D3 increased the effect of aCD 45 on AA 
release. Equal volumes o f THP-1 cells at 5x105 cells/ml, either treated or not treated with 
vitamin D3 (0.1 pM), were labeled and challenged as in Fig. 3. Values represent cpm 
released in 200 pi of cell-free supernatants above control, and are averages o f duplicates ± 
range.
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Several other bacterial amphiphiles have been shown to bind CD 14, including MPL, 
DPL, and LTA (See Chapter 3). Other agents, including C2 ceramide, sphingomyelinase 
(SMase), and phorbol myristate acetate (PMA), activate AA metabolism independent of 
CD 14 binding. Anti-CD45 increased release from cells treated with all o f the CD 14 
ligands (Figure 13), but none of the CD 14-independent agents (Figure 14).
^  1800 -I
J2
o
E
OLo,
O
1LI
CD<
UJ
- I
UJ
K
3
xfO
1600
1400 -
1200
1000
800 -
600 -
No anti-CD45 
With anti-CD45
LPS MPL-s LTA DPL
Figure 13. aCD45 affects AA release activated by other CD14 ligands: MPL-s, 
DPL, and LTA. D3-pretreated THP-1 cells were labeled as in Fig. 3, and challenged 
with medium alone, or 1 pg/ml LPS R595, MPL-s, DPL, or LTA (E. faecalis) for 2 hr. 
Values represent cpm released in 200 pi of cell-free supernatants above control, and are 
averages of duplicates ± range. The experiment was repeated 3 times.
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LPS C2 SMase PMA TNF
Figure 14. aCD45 did not affect 3H-AA release activated by agents using CD14- 
independent signaling. D3 pretreated THP-1 cells were labeled as in Fig. 3 and 
challenged with 50 jjM  C2 ceramide, 0.5 U/ml SMase, 10 ng/ml LPS for 2 hr, or 20 ng/ml 
TNF, 30 ng/ml PMA for 5 hr. Values represent cpm released in 200 |il cell-free 
supernatants above control, and are averages of duplicates ± range. The experiments were 
repeated 2-3 times.
Figure 15 shows that anti-CD45 also increased production of TNFa from cells 
treated with MPL-s, one of the CD 14 ligands.
Finally, anti-CD 14 UCHM-1 activates AA release from THP-1 cells, and may 
serve as an LPS agonist, directly activating signaling by binding to the LPS-binding site on 
CD 14. Isotype-matched control IgCna was shown to have no effect on AA release (Fig. 
6). To further confirm its role as an LPS agonist, I was able to show that, like LPS, anti-
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CD 14 UCHM-1 induced only PGE2 and not LTC» production, giving high PGE2/LTC4 
ratios (Fig. 16), was able to desensitize cells to LPS challenge (Fig. 17), and had very little 
effect on cells without D3 pretreatment (Fig. 18). Figure 18 also shows that anti-CD45 
significantly increased AA release from cells treated with anti-CD 14.
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Figure 15. aCD45 increased release of TN Fa from THP-1 cells challenged with 
MPL-s. D3-pretreated THP-1 cells were challenged for 20 hr with MPL-s at 
concentrations shown, with or without aCD45 2D1. Supernatants were assayed for 
TNFa by ELISA according to Quantikine instructions. TNFa in pg/ml was calculated 
from a standard curve.
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Control LPS Anti-CD14
Figure 16. aCD14 UCHM-1 induced PGE2 production. Supernatants from D3- 
pretreated THP-1 cells that had been challenged with aCD14 UCHM-1 were assayed for 
PGE2 and LTC4 using EIA, according to manufacturer’s instructions. PGE2 & LTC4 in 
pg/ml were calculated from standard curves. Values are molar ratios o f PGE2 to LTC4. 
and are averages of duplicates ± range.
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Figure 17. Desensitization of THP-1 cells with aCD14. D3-pretreated THP-1 cells 
were treated with medium alone or 1 jig/ml aCD14 UCHM-1 for 2 hrs. Cells were then 
washed and labeled overnight with 3H-AA. They were washed again and challenged in 24 
well plates (5x10s cells/ml) with LPS R595 for 2 hr. 200 1̂ of cell-free supernatants were 
counted. Values represent cpm released above control, and are averages o f duplicates.
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Figure 18. Vitamin D3 pretreatment increased the sensitivity of THP-1 cells to 
challenge with aCD14, and the effect of aCD45. THP-1 cells, D3 treated or untreated, 
were labeled and challenged with aCD14 UCHM-1, with or without aCD45 2D1, for 2 
hr. Values represent cpm released in 200 |ji of cell-free supernatants above control, and 
are averages o f duplicates ± range.
LPS treatm ent caused increased phosphorylation of CD45. The
phosphorylation of tyrosines on CD45 has been shown to modify PTPase activity. The 
terminal PTPase domain on CD45 appears to be an autodephosphorylation activity (102). 
In order to determine whether LPS or anti-CD45 mAb affected PTPase activity, the 
phosphorylation o f CD45 was compared under various conditions using anti-
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phosphotyrosine mAbs to stain immunoblots o f CD4S immunoprecipitates from lysed 
THP-1 cells. There was an apparent transient increase in the phosphotyrosine stain after 5 
minutes o f incubation with LPS (Fig. 19).
Figure 19. LPS increased phosphorylation of CD45 within 15 min after treatment.
D3-pretreated THP-1 cells were treated with LPS for 0, 5, 15, 30, and 45 min (lanes 2-6), 
and then lysed in lysis buffer containing NaV04 and PhAsO to inhibit further PTPase 
activity. Lysates were immunoprecipitated with aCD45 as described in Materials & 
Methods, and run on 7.5% SDS-PAGE mini-gels. These were then blotted onto PDVF 
membranes and stained with biotinylated aphosphotyrosine mAb. The immunoblots were 
developed and films exposed using ECL. Lane 1, Protein standard; Lane 7, positive 
control.
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DISCUSSION
The data reported provide indirect evidence for a role of the CD45 protein 
tyrosine phosphatase in signaling activated by LPS through CD 14. More direct evidence 
could be obtained by using CD45 knock-out mutants. Our inquiries regarding CD45 
knock-out mice or monocyte cell lines were regrettably unsuccessful. Despite the 
limitations o f indirect studies, however, this is the first study to show any relationship 
between CD4S and signaling for arachidonic acid release, or specifically via CD 14.
Studies on T cells have now been done that provide both indirect (using mAbs) and direct 
(using CD45 knock-outs) evidence of CD45 involvement in regulation o f signaling 
(reviewed in (93)). Tyrosine kinases of the src family in CD45-deficient T cells are 
hyperphosphorylated on tyrosines at inhibitory sites. In these cases, CD4S activates the 
kinases by removing the phosphate groups from these sites. Because this occurs in resting 
cells, CD4S apparently serves to maintain a state of readiness prior to TCR-antigen 
binding. This also implies that CD45 must be in close proximity to these substrates even 
in resting cells. This is consistent with our data showing constitutively high expression of 
CD4S on resting cells. Some tyrosine kinases are inactivated by removal of phosphates 
from positive regulatory sites, so that CD4S can also be a down-regulator of tyrosine 
kinase activity.
Consistent with this model in T cells, tyrosine kinases appear to be the substrates 
for dephosphorylation by CD4S in monocytes, and this activity regulates signal 
transduction (61,77). Signaling through CD14 activates tyrosine phosphorylation (60),
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and tyrosine phosphorylation activated by LPS is associated with release of arachidonic 
acid metabolites (33). This suggests the possibility that signaling by LPS through CD14 
activates arachidonic acid metabolism via a tyrosine kinase signaling cascade. This study 
was undertaken to determine whether CD45 protein tyrosine phosphatase plays a role in 
regulating that pathway. As suggested in the T cell model, CD45 may simply maintain a 
state of readiness by keeping tyrosine kinases from being phosphorylated at inhibitory 
sites. This is supported by the fact that addition of anti-CD45 18 hours before challenge 
had a greater effect than addition just prior to challenge (Fig. 4a,b), that anti-CD45 had 
little effect by itself (Fig. S), and by the fact that anti-CD45 had no effect on 
desensitization by LPS (Fig. 9). Cross-linking of anti-CD45 appears to have inhibited the 
phosphatase activity, so that tyrosine kinase signaling was inhibited by phosphorylation
(Fig- 8).
The possibility that some of the effects seen were due to binding of anti-CD45 to Fc 
receptors was considered. However, isotype matched control mAbs had no effect (Fig.
5). Also, activation by anti-CD45 and LPS led to production of PGE2, but not LTB4 or 
LTC4, consistent with other studies showing that LPS only activates cyclo-oxygenase and 
not 5’-lipoxygenase (31,33,105), and suggests that anti-CD45 simply increased signaling 
by LPS, but did not activate other pathways. Activation through FcRy has been shown to 
lead to production of LTB4 from neutrophils and monocytes (49,83).
Several lines of evidence were used to link these effects of anti-CD45 with 
signaling through CD 14. First, it was shown that there was little effect with no serum in 
the challenge medium (Fig. 11). Signaling via CD 14 by LPS requires a serum LPS binding
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protein, LBP, for transfer o f monomers to CD14 (70,108). Absence of LBP reduces 
cellular sensitivity to LPS, but LPS can still signal via CD 14-independent pathways (68). 
The reduced effect of anti-CD45 in medium without serum suggests that CD45 may be 
more active in regulating CD 14-dependent signaling than CD 14-independent signaling. 
Similarly, pretreatment o f the cells with vitamin D3, which increases expression of CD 14 
(see Chapter 2) also increased the effect of anti-CD45 (Fig. 12). Without D3 
pretreatment, anti-CD45 had almost no effect except at the highest LPS concentration.
Finally, other CD 14 ligands, including MPL, DPL, LTA, and an LPS agonist mAb 
to CD 14, also were much more potent for AA release in the presence of anti-CD45 (Fig. 
13). However, none of the activating agents that do not bind CD14 showed this 
synergistic effect with anti-CD45 (Fig. 14.)
There is evidence in T cells that engagement of the extracellular domain o f CD45 by 
other glycosylated cell surface molecules such as adhesion molecules (or CD45-specific 
mAbs) can modify the protein tyrosine phosphatase activity of the cytosolic domain (93). 
We attempted to visualize changes in the phosphorylation state o f CD4S before and after 
treatment with LPS, since autodephosphorylation is an indication of PTPase activity 
(102). This would provide a more direct connection between LPS signaling and CD45.
On my initial immunoblots, there was an apparent increase in phosphorylation of CD4S at 
5 min after stimulation of the cells with LPS (Fig. 19). These experiments need to be 
repeated and carefully standardized for the amount o f protein/well, and then analyzed by 
densitometry. This assay could then be expanded to look at the kinetics of 
autodephosphorylation of CD45, and the effects of this change in activity on function in 
terms of activation and desensitization of the arachidonic acid metabolism pathway.
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Tyrosine phosphorylation has been correlated with all indices o f macrophage 
activation studied so far (24,32-34,37,53,99). Although CD45 appears to play a role in 
LPS signaling, the broad range of pathways affected by CD45 in macrophages 
(39,53,61,64,77,101) suggests the possibility that CD45 does not specifically associate 
with any particular receptor. It may instead affect generalized signaling via src family 
protein tyrosine kinases (PTK) by maintaining the phosphoiylation-dephosphorylation 
equilibrium at a level that ensures readiness to respond through any pathways utilizing a 
PTK cascade. If  this is the case, it may be possible to reduce sensitivity of macrophages 
to multiple signals by inactivating CD45. CD45-deficient systems could be used to study 
this. However, our cross-linking studies suggested that cross-linking CD45 molecules 
may inhibit the PTPase activity. If cross-linking CD45 during a desensitization period 
could block response to subsequent challenge with LPS, this would also support the 
readiness hypothesis. This may therefore be critical to understanding the desensitization 
phenomenon. It could also provide a mechanism for down-regulation of macrophage 
activation as a potential therapeutic model. It is along these lines that future studies are 
being designed.
It was also interesting that in experiments using conditions that favored CD 14- 
independent signaling, there was a consistent slight to moderate reduction in AA release, 
rather than the increase seen with CD 14 ligands. Further studies would need to be done 
to look at the statistical significance of these reductions. If they were significant 
reductions, it would be interesting to look at the possibility that CD45 regulates these 
signaling pathways as well, but in these cases it decreases responsiveness. At least two 
models are conceivable. First, the kinases involved in CD 14 independent pathways may
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become phosphorylated on activation sites rather than inhibitory sites, so that CD4S 
PTPase activity inactivates them. This leads to a conceptual model of a single regulatory 
system (CD45 dephosphorylation of kinases) that serves to activate some pathways while 
at the same time inactivating others. This would ensure patterns of responses depending 
on the type o f stimuli present. Another possibility is a kinetic model in which early 
signaling pathways are maintained in a state of readiness by the constitutive activity of 
CD4S, but binding o f a ligand to a receptor in proximity to the extracellular domain of 
CD45 may alter that activity. Activation of later signaling pathways might then be 
inhibited due to this change in PTPase activity which may no longer maintain the state of 
readiness to respond. These models could be explored using a phosphatase assay to 
determine activity o f the CD45 PTPase before and after challenge. We are developing a 
colorimetric assay for looking at PTPase activity on immunoprecipitates of CD4S.
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
CHAPTER 6 
CONCLUSIONS AND FUTURE STUDIES
Elucidation of signal transduction pathways in macrophages will not only 
improve our overall understanding of these complex and critical players in immune 
responses, but also may expose exploitable mechanisms for treatment or prevention o f 
conditions caused by immune dysfunction. These studies were undertaken to explore 
three steps of signal transduction as they relate to LPS activation of macrophages:
1. Recognition of LPS by cells, including factors affecting cellular sensitivity,
2. Signaling components in the activation of arachidonic acid by LPS, and
3. Regulatory mechanisms modulating arachidonic acid metabolism.
It was first necessary to characterize a monocyte/macrophage cell system in order to 
maximize consistency and reproducibility of results, and to rule out effects o f the 
treatments of other parameters of cellular responses such as viability, receptor expression, 
and lipid pool labeling. The studies reported in Chapter 2 demonstrate that vitamin D3- 
pretreated THP-1 monocytic cells provided an excellent cell system for studies on 
arachidonic acid metabolism.
Macrophages recognize LPS in at least two ways. The primary signaling receptor for 
LPS is CD 14, a glycosylphosphatidylinositol-linked protein that has been shown to be 
involved in the activation of protein tyrosine kinases and several signaling pathways.
LPS also activates cells in a CD 14-independent manner, either by some other receptor or 
by non-specific interaction with the membrane. It has also been proposed that cells
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recognize LPS as a mimic o f an important intracellular second messenger, ceramide. The 
work presented in Chapter 3 explored relative potencies o f several bacterial amphiphiles, 
most of which have also been shown to bind CD 14, and yet can have very different 
effects. These data, along with current literature, were used to develop a model of 
sensitivity o f macrophages to LPS based on supramolecular structure and aggregate 
stability. Binding to CD 14 requires presentation as monomers carried by LPS binding 
proteins. Inaccessibility of monomers to LBP due to supramolecular structure would 
limit signaling through this pathway. However, aggregate structure might affect CD 14- 
independent signaling very differently than CD 14-dependent signaling, so that various 
amphiphiles might activate the two pathways with very different frequencies, resulting in 
varying potencies and potentially unique overall responses. This could explain why some 
LPS preparations are quite toxic while others can be protective in vivo. This work in on­
going through a collaboration with Ribi ImmunoChem Research.
Chapter 4 explored the LPS/ceramide mimicry model in terms of arachidonic acid 
metabolism. This model provides a basis for studying not only the recognition of cells by 
LPS, but also of several signaling components involved in macrophage activation by 
LPS. The results presented in Chapter 4 showed that the mimicry o f ceramide by LPS is 
not simple, and although they may share some signaling components, LPS has unique 
functions including the ability to desensitize cells to subsequent challenge and the 
activation of cyclo-oxygenase. There is a possibility that these two functions are related 
due to an autocrine effect by prostaglandin or another product related to the cyclo- 
oxygenase activation. Future studies will be looking at other lipids released by activated
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macrophages, and through the use o f creative co-culture experiments it will be possible to 
further investigate the possible autocrine/paracrine effects by released mediators. These 
studies will be especially important in view of recent evidence that massive endothelial 
apoptosis in the microvasculature o f multiple organs plays an important role in the 
pathogenesis of septic shock. Ceramide has been shown to be an inducer o f  apoptosis, 
and it is released in cells activated by TNFa. This raises the possibility that LPS may not 
only activate the release of TNFa, but may also further exacerbate the apoptotic events 
through mimicry of ceramide.
The desensitization phenomenon is intriguing, and the mechanism remains unknown. 
As mentioned above, there may be an autocrine factor involved. However, even that 
would not explain what exactly occurs inside the cell to create the refractory state 
prohibiting further activation of the cell by LPS. Activation and desensitization have 
both been associated with the activity of protein tyrosine kinases and could therefore be 
functions of the phosphorylation-dephosphorylation dynamics o f these enzymes. Many 
protein tyrosine kinases are regulated by their own phosphorylation state. In T cells, 
CD4S deficient mutants are hyperphosphorylated on the src family PTKs, and are unable 
to respond to antigen binding by the TCR. This provides a model in which 
hyperphosphorylation causes a refractory, or desensitized state. In order to explore a 
similar mechanism for desensitization in macrophages, it was hypothesized that CD4S 
might also maintain a state of readiness to respond by dephosphorylating the src PTKs 
involved in signaling via CD 14. Using anti-CD45 mAbs, it was demonstrated that CD4S 
does play a role in the activation of arachidonic acid metabolism by LPS. The lack of a
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CD45-deficient macrophage cell system or an anti-CD45 mAb that blocked the PTPase 
activity prevented a careful exploration of the role of CD45 in the desensitization 
phenomenon. However, cross-linking of CD45 appeared to inhibit the PTPase, and 
preliminary studies showed that this also desensitized cells to subsequent challenge. This 
would suggest that blocking CD4S activity prevented the state of readiness to respond by 
allowing tyrosine phosphorylation on inhibitory sites o f the PTKs. However, several 
more studies would need to be done to determine whether this is also part of mechanism 
o f LPS desensitization.
In summary, three mechanisms of modulating responsiveness to LPS have been 
examined, including modification of the supramolecular structure of LPS preparations, an 
autocrine or paracrine effect related to activation of the cyclo-oxygenase pathway, and 
alteration o f the phosphorylation state of PTK signaling cascades. Exploitation of these 
mechanisms may be possible, and may prove to be therapeutic or prophylactic for 
pathological conditions resulting from excessive inflammation or other immune 
dysfunction. Applications may include treatment of asthma, septic shock, cardiac 
ischemia/reperfiision injury, organ transplants, and atherosclerosis.
The outcome of any set of conditions in a cell or tissue appears to depend not on a 
linear progression of events, but on the relative frequency o f  many related events. For 
example, whether a signal results in mitogenesis or cell cycle arrest appears to depend on 
the intracellular ratio of two important second messengers with opposing effects: 
diacylglycerol and ceramide. Also, the activation of tyrosine kinases appears to be due to 
the relative amount of phosphorylation of the entire cascade, not a simple on/off switch.
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The ratio of prostaglandins and leukotrienes appears to be critical in the overall 
inflammatory response in a given situation, rather than simply the presence o f one or the 
other. Apoptosis is being exposed as a very important part of many processes including 
beneficial ones (selection of an appropriate set of T cells that survive development in the 
thymus, destruction o f cancerous cells, and embryonic development), and harmful ones 
(destruction of tissue in septic shock, heart attack, etc). It is known that TNFa is an 
important inducer of apoptosis, but the identity of the molecule that balances that effect is 
unknown. It seems very possible that it might be revealed by these continuing studies on 
the modulation of macrophage activation.
The findings presented in this thesis provide clues to the complexities o f LPS- 
induced signal transduction in macrophages, but the picture is far from complete. The 
systems of checks and balances for maintaining an effective and appropriate response to 
bacterial infection without causing undue damage are intertwined in a dynamic network. 
This prohibits simple answers, and consistently provides more questions with every step 
forward. In the 1960’s, Ivan L. Bennett, Jr., working at Johns Hopkins, expressed both 
the fascination and frustration researchers face in these complex systems:
“Endotoxins possess an intrinsic fascination that is nothing less than fabulous. 
They seem to have been endowed by nature with virtues and vices in the exact and 
glamorous proportions needed to render them irresistible to any investigator who comes 
to know them.” (78).
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